{"acid": [1, 13, 23, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 81, 82, 83, 84, 85, 86, 87, 88, 89, 91, 92, 94, 95, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 477, 478, 479, 480, 481, 482, 483, 484, 487, 488, 490, 491, 492, 493, 494, 495, 498, 499, 500, 501, 502, 503, 504, 505, 518, 519, 522, 523, 524, 525, 526, 527, 530, 531, 532, 534, 539, 541, 542, 543, 544, 697, 700, 703, 706, 707, 708, 711, 712, 713, 714, 715, 718, 719, 720, 721, 747, 748, 749, 750, 757, 766, 892, 893, 896, 897, 900, 901, 904, 905, 906, 909, 910, 913, 914, 1013, 1014, 1015, 1016, 1091, 1120, 1121, 1124, 1125, 1126, 1127, 1137, 1138, 1141, 1144, 1145, 1802, 1804, 1831, 1922, 1925, 1928, 1929, 1930, 1931, 1932, 1935, 1936, 1937, 1939, 1941, 1942, 1943, 1944, 1947, 1948, 1950, 1952, 1954, 1957, 1959, 1960, 1962, 1964, 1968, 1970, 1971, 1973, 1975, 1977, 1978, 1979, 1980, 1981, 1983, 1984, 1985, 1987, 1988, 1989, 1990, 1991, 1997, 1998, 2001, 2002, 2005, 2006, 2009, 2010, 2012, 2013, 2073, 2074, 2075, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2379, 2380, 2383, 2384, 2393, 2394, 2397, 2398, 2445, 2446, 2731, 2759, 2760], "aid": [1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 291, 292, 293, 294, 295, 296, 297, 298, 301, 302, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 317, 318, 319, 320, 321, 322, 323, 324, 325, 327, 328, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 386, 402, 403, 404, 405, 406, 407, 425, 426, 435, 441, 442, 443, 450, 451, 452, 533, 534, 575, 576, 577, 578, 579, 580, 581, 582, 583, 585, 586, 587, 588, 589, 592, 593, 594, 595, 640, 670, 671, 672, 678, 679, 680, 681, 665, 666, 857, 856], "assay_component_name": ["ACEA_ER_80hr", "APR_HepG2_CellLoss_24hr", "APR_HepG2_CellLoss_72hr", "ATG_Ahr_CIS", "ATG_AP_1_CIS", "ATG_AP_2_CIS", "ATG_BRE_CIS", "ATG_C_EBP_CIS", "ATG_CRE_CIS", "ATG_DR4_LXR_CIS", "ATG_DR5_RAR_CIS", "ATG_E_Box_CIS", "ATG_E2F_CIS", "ATG_EGR_CIS", "ATG_ERE_CIS", "ATG_Ets_CIS", "ATG_FoxA2_CIS", "ATG_FoxO_CIS", "ATG_GATA_CIS", "ATG_GLI_CIS", "ATG_GRE_CIS", "ATG_HIF1a_CIS", "ATG_HNF6_CIS", "ATG_HSE_CIS", "ATG_IR1_CIS", "ATG_ISRE_CIS", "ATG_MRE_CIS", "ATG_Myb_CIS", "ATG_Myc_CIS", "ATG_NF_kB_CIS", "ATG_NFI_CIS", "ATG_NRF1_CIS", "ATG_NRF2_ARE_CIS", "ATG_Oct_MLP_CIS", "ATG_p53_CIS", "ATG_Pax6_CIS", "ATG_PBREM_CIS", "ATG_PPRE_CIS", "ATG_PXRE_CIS", "ATG_RORE_CIS", "ATG_Sox_CIS", "ATG_Sp1_CIS", "ATG_SREBP_CIS", "ATG_STAT3_CIS", "ATG_TGFb_CIS", "ATG_VDRE_CIS", "ATG_Xbp1_CIS", "ATG_AR_TRANS", "ATG_CAR_TRANS", "ATG_ERa_TRANS", "ATG_ERRa_TRANS", "ATG_ERRg_TRANS", "ATG_FXR_TRANS", "ATG_GR_TRANS", "ATG_HNF4a_TRANS", "ATG_LXRa_TRANS", "ATG_LXRb_TRANS", "ATG_NURR1_TRANS", "ATG_PPARa_TRANS", "ATG_PPARd_TRANS", "ATG_PPARg_TRANS", "ATG_PXR_TRANS", "ATG_RARa_TRANS", "ATG_RARb_TRANS", "ATG_RARg_TRANS", "ATG_RORb_TRANS", "ATG_RORg_TRANS", "ATG_RXRa_TRANS", "ATG_RXRb_TRANS", "ATG_THRa1_TRANS", "ATG_VDR_TRANS", "BSK_3C_Eselectin", "BSK_3C_HLADR", "BSK_3C_ICAM1", "BSK_3C_IL8", "BSK_3C_MCP1", "BSK_3C_MIG", "BSK_3C_Proliferation", "BSK_3C_SRB", "BSK_3C_Thrombomodulin", "BSK_3C_TissueFactor", "BSK_3C_uPAR", "BSK_3C_VCAM1", "BSK_4H_Eotaxin3", "BSK_4H_MCP1", "BSK_4H_Pselectin", "BSK_4H_SRB", "BSK_4H_uPAR", "BSK_4H_VCAM1", "BSK_4H_VEGFRII", "BSK_BE3C_HLADR", "BSK_BE3C_IL1a", "BSK_BE3C_IP10", "BSK_BE3C_MIG", "BSK_BE3C_MMP1", "BSK_BE3C_PAI1", "BSK_BE3C_SRB", "BSK_BE3C_tPA", "BSK_BE3C_uPA", "BSK_BE3C_uPAR", "BSK_CASM3C_HLADR", "BSK_CASM3C_IL6", "BSK_CASM3C_IL8", "BSK_CASM3C_LDLR", "BSK_CASM3C_MCP1", "BSK_CASM3C_MCSF", "BSK_CASM3C_MIG", "BSK_CASM3C_Proliferation", "BSK_CASM3C_SAA", "BSK_CASM3C_SRB", "BSK_CASM3C_Thrombomodulin", "BSK_CASM3C_TissueFactor", "BSK_CASM3C_uPAR", "BSK_CASM3C_VCAM1", "BSK_hDFCGF_CollagenIII", "BSK_hDFCGF_EGFR", "BSK_hDFCGF_IL8", "BSK_hDFCGF_IP10", "BSK_hDFCGF_MCSF", "BSK_hDFCGF_MIG", "BSK_hDFCGF_MMP1", "BSK_hDFCGF_PAI1", "BSK_hDFCGF_Proliferation", "BSK_hDFCGF_SRB", "BSK_hDFCGF_TIMP1", "BSK_hDFCGF_VCAM1", "BSK_KF3CT_ICAM1", "BSK_KF3CT_IL1a", "BSK_KF3CT_IP10", "BSK_KF3CT_MCP1", "BSK_KF3CT_MMP9", "BSK_KF3CT_SRB", "BSK_KF3CT_TIMP2", "BSK_KF3CT_uPA", "BSK_LPS_CD40", "BSK_LPS_Eselectin", "BSK_LPS_IL1a", "BSK_LPS_IL8", "BSK_LPS_MCP1", "BSK_LPS_MCSF", "BSK_LPS_PGE2", "BSK_LPS_SRB", "BSK_LPS_TissueFactor", "BSK_LPS_TNFa", "BSK_LPS_VCAM1", "BSK_SAg_CD38", "BSK_SAg_CD40", "BSK_SAg_CD69", "BSK_SAg_Eselectin", "BSK_SAg_IL8", "BSK_SAg_MCP1", "BSK_SAg_MIG", "BSK_SAg_PBMCCytotoxicity", "BSK_SAg_Proliferation", "BSK_SAg_SRB", "OT_AR_ARSRC1_0480", "OT_AR_ARSRC1_0960", "OT_ER_ERaERa_0480", "OT_ER_ERaERa_1440", "OT_ER_ERaERb_0480", "OT_ER_ERaERb_1440", "OT_ER_ERbERb_0480", "OT_ER_ERbERb_1440", "OT_ERa_GFPERaERE_0120", "OT_ERa_GFPERaERE_0480", "OT_FXR_FXRSRC1_0480", "OT_FXR_FXRSRC1_1440", "OT_NURR1_NURR1RXRa_0480", "OT_NURR1_NURR1RXRa_1440", "OT_PPARg_PPARgSRC1_0480", "OT_PPARg_PPARgSRC1_1440", "TOX21_AR_BLA_Agonist_ratio", "TOX21_AR_BLA_Antagonist_ratio", "TOX21_AR_BLA_Antagonist_viability", "TOX21_AR_LUC_MDAKB2_Agonist", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", "TOX21_Aromatase_Inhibition", "TOX21_Aromatase_Inhibition_viability", "TOX21_ELG1_LUC_Agonist", "TOX21_ELG1_LUC_Agonist_viability", "TOX21_ERa_BLA_Agonist_ratio", "TOX21_ERa_BLA_Antagonist_ratio", "TOX21_ERa_BLA_Antagonist_viability", "TOX21_ERa_LUC_VM7_Agonist", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", "TOX21_GR_BLA_Agonist_ratio", "TOX21_GR_BLA_Antagonist_ratio", "TOX21_GR_BLA_Antagonist_viability", "TOX21_MMP_ratio", "TOX21_PPARg_BLA_Agonist_ratio", "TOX21_TR_LUC_GH3_Antagonist", "TOX21_TR_LUC_GH3_Antagonist_viability", "TOX21_AhR_LUC_Agonist", "TOX21_AhR_LUC_Agonist_viability", "TOX21_ARE_BLA_Agonist_ratio", "TOX21_HSE_BLA_Agonist_ratio", "TOX21_p53_BLA_p1_ratio", "TOX21_FXR_BLA_Agonist_ratio", "TOX21_FXR_BLA_Antagonist_ratio", "TOX21_FXR_BLA_Antagonist_viability", "TOX21_PPARd_BLA_Agonist_ratio", "TOX21_PPARd_BLA_Antagonist_ratio", "TOX21_PPARd_BLA_Antagonist_viability", "TOX21_PPARg_BLA_Antagonist_ratio", "TOX21_PPARg_BLA_Antagonist_viability", "TOX21_VDR_BLA_Agonist_ratio", "TOX21_VDR_BLA_Antagonist_ratio", "TOX21_VDR_BLA_Antagonist_viability", "TOX21_DT40", "TOX21_ARE_BLA_agonist_viability", "TOX21_HSE_BLA_agonist_viability", "TOX21_p53_BLA_p1_viability", "TOX21_FXR_BLA_agonist_viability", "TOX21_PPARd_BLA_Agonist_viability", "ATG_XTT_Cytotoxicity", "TOX21_p53_BLA_p2_ratio", "TOX21_p53_BLA_p2_viability", "TOX21_p53_BLA_p3_ratio", "TOX21_p53_BLA_p3_viability", "TOX21_p53_BLA_p4_ratio", "TOX21_p53_BLA_p4_viability", "TOX21_p53_BLA_p5_ratio", "TOX21_p53_BLA_p5_viability", "TOX21_VDR_BLA_Agonist_viability", "TOX21_ESRE_BLA_ratio", "TOX21_ESRE_BLA_viability", "TOX21_NFkB_BLA_agonist_ratio", "TOX21_NFkB_BLA_agonist_viability", "TOX21_RAR_LUC_Agonist", "TOX21_RAR_LUC_Agonist_viability", "TOX21_RORg_LUC_CHO_Antagonist", "TOX21_RORg_LUC_CHO_Antagonist_viability", "BSK_MyoF_SRB", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", "TOX21_RXR_BLA_Agonist_ratio", "TOX21_RXR_BLA_Agonist_viability", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", "TOX21_RAR_LUC_Antagonist", "TOX21_RAR_LUC_Antagonist_viability", "TOX21_H2AX_HTRF_CHO_Agonist_ratio", "TOX21_AP1_BLA_Agonist_ratio", "TOX21_AP1_BLA_Agonist_viability", "ACEA_AR_agonist_AUC_viability", "ACEA_ER_AUC_viability", "ACEA_AR_antagonist_AUC_viability", "TOX21_TSHR_HTRF_Agonist_ratio", "TOX21_TSHR_HTRF_Antagonist_ratio", "TOX21_TSHR_wt_Agonist_HTRF_ratio", "TOX21_CAR_Agonist", "TOX21_CAR_Agonist_viability", "TOX21_CAR_Antagonist", "TOX21_CAR_Antagonist_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", "TOX21_ERR_Agonist", "TOX21_ERR_Antagonist", "TOX21_ERR_viability", "TOX21_H2AX_HTRF_CHO_viability", "TOX21_HDAC_Inhibition", "TOX21_HDAC_Inhibition_viability", "TOX21_HRE_BLA_Agonist_ratio", "TOX21_HRE_BLA_Agonist_viability", "TOX21_PGC_ERR_Agonist", "TOX21_PGC_ERR_Antagonist", "TOX21_PGC_ERR_viability", "TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEK293_FLO_16hr_viability", "TOX21_RT_HEK293_FLO_24hr_viability", "TOX21_RT_HEK293_FLO_32hr_viability", "TOX21_RT_HEK293_FLO_40hr_viability", "TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEK293_GLO_16hr_viability", "TOX21_RT_HEK293_GLO_24hr_viability", "TOX21_RT_HEK293_GLO_32hr_viability", "TOX21_RT_HEK293_GLO_40hr_viability", "TOX21_RT_HEPG2_FLO_08hr_viability", "TOX21_RT_HEPG2_FLO_16hr_viability", "TOX21_RT_HEPG2_FLO_24hr_viability", "TOX21_RT_HEPG2_FLO_32hr_viability", "TOX21_RT_HEPG2_FLO_40hr_viability", "TOX21_RT_HEPG2_GLO_08hr_viability", "TOX21_RT_HEPG2_GLO_16hr_viability", "TOX21_RT_HEPG2_GLO_32hr_viability", "TOX21_RT_HEPG2_GLO_40hr_viability", "TOX21_SHH_3T3_GLI3_Agonist", "TOX21_SHH_3T3_GLI3_Agonist_viability", "TOX21_SHH_3T3_GLI3_Antagonist", "TOX21_SHH_3T3_GLI3_Antagonist_viability", "TOX21_ERb_BLA_Antagonist_ratio", "TOX21_ERb_BLA_Antagonist_viability", "TOX21_ERb_BLA_Agonist_ratio", "TOX21_ERb_BLA_Agonist_viability", "TOX21_PR_BLA_Agonist_ratio", "TOX21_PR_BLA_Agonist_viability", "TOX21_PR_BLA_Antagonist_ratio", "TOX21_PR_BLA_Antagonist_viability", "TOX21_DT40_100", "TOX21_DT40_657", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", "TOX21_RT_HEPG2_GLO_24hr_viability", "TOX21_PXR_viability", "TOX21_PXR_agonist", "TOX21_TRHR_HEK293_agonist", "TOX21_TRHR_HEK293_antagonist", "TOX21_CASP3_HEPG2", "TOX21_CASP3_HEPG2_viability", "TOX21_CASP3_CHO", "TOX21_CASP3_CHO_viability", "TOX21_SBE_BLA_Antagonist_ratio", "TOX21_SBE_BLA_Antagonist_viability", "TOX21_SBE_BLA_Agonist_ratio", "TOX21_SBE_BLA_Agonist_viability", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist", "CCTE_Harrill_HTTr_Viability_MCF7", "CCTE_Harrill_HTTr_Apoptosis_MCF7", "BSK_BF4T_SRB", "BSK_IMphg_SRB", "BSK_IMphg_SRB.Mphg"], "assay_component_desc": ["ACEA_ER_80hr, is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", "APR_HepG2_CellLoss_24hr, is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "APR_HepG2_CellLoss_72hr, is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "ATG_Ahr_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_AP_1_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_AP_2_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_BRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_C_EBP_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_CRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_DR4_LXR_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_DR5_RAR_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_E_Box_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_E2F_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_EGR_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_ERE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_Ets_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_FoxA2_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_FoxO_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_GATA_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_GLI_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_GRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_HIF1a_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_HNF6_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_HSE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_IR1_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_ISRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_MRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_Myb_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_Myc_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_NF_kB_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_NFI_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_NRF1_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_NRF2_ARE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_Oct_MLP_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_p53_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_Pax6_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_PBREM_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_PPRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_PXRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_RORE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_Sox_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_Sp1_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_SREBP_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_STAT3_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_TGFb_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_VDRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_Xbp1_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_AR_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_CAR_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_ERa_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_ERRa_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_ERRg_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_FXR_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_GR_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_HNF4a_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_LXRa_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_LXRb_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_NURR1_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_PPARa_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_PPARd_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_PPARg_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_PXR_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_RARa_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_RARb_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_RARg_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_RORb_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_RORg_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_RXRa_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_RXRb_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_THRa1_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_VDR_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_3C_Eselectin is an assay component measured in the BSK_3C assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", "BSK_3C_HLADR is an assay component measured in the BSK_3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", "BSK_3C_ICAM1 is an assay component measured in the BSK_3C assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_3C_IL8 is an assay component measured in the BSK_3C assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", "BSK_3C_MCP1 is an assay component measured in the BSK_3C assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_3C_MIG is an assay component measured in the BSK_3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", "BSK_3C_Proliferation is an assay component measured in the BSK_3C assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", "BSK_3C_SRB is an assay component measured in the BSK_3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_3C_Thrombomodulin is an assay component measured in the BSK_3C assay. It measures Thrombomodulin antibody related to regulation of gene expression using ELISA technology.", "BSK_3C_TissueFactor is an assay component measured in the BSK_3C assay. It measures Tissue Factor antibody related to regulation of gene expression using ELISA technology.", "BSK_3C_uPAR is an assay component measured in the BSK_3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", "BSK_3C_VCAM1 is an assay component measured in the BSK_3C assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_4H_Eotaxin3 is an assay component measured in the BSK_4H assay. It measures Eotaxin-3 antibody related to regulation of gene expression using ELISA technology.", "BSK_4H_MCP1 is an assay component measured in the BSK_4H assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_4H_Pselectin is an assay component measured in the BSK_4H assay. It measures P-Selectin antibody related to regulation of gene expression using ELISA technology.", "BSK_4H_SRB is an assay component measured in the BSK_4H assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_4H_uPAR is an assay component measured in the BSK_4H assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", "BSK_4H_VCAM1 is an assay component measured in the BSK_4H assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_4H_VEGFRII is an assay component measured in the BSK_4H assay. It measures VEGFRII antibody related to regulation of gene expression using ELISA technology.", "BSK_BE3C_HLADR is an assay component measured in the BSK_BE3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", "BSK_BE3C_IL1a is an assay component measured in the BSK_BE3C assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", "BSK_BE3C_IP10 is an assay component measured in the BSK_BE3C assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", "BSK_BE3C_MIG is an assay component measured in the BSK_BE3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", "BSK_BE3C_MMP1 is an assay component measured in the BSK_BE3C assay. It measures MMP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_BE3C_PAI1 is an assay component measured in the BSK_BE3C assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_BE3C_SRB is an assay component measured in the BSK_BE3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_BE3C_tPA is an assay component measured in the BSK_BE3C assay. It measures tPA antibody related to regulation of gene expression using ELISA technology.", "BSK_BE3C_uPA is an assay component measured in the BSK_BE3C assay. It measures uPA antibody related to regulation of gene expression using ELISA technology.", "BSK_BE3C_uPAR is an assay component measured in the BSK_BE3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_HLADR is an assay component measured in the BSK_CASM3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_IL6 is an assay component measured in the BSK_CASM3C assay. It measures IL-6 antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_IL8 is an assay component measured in the BSK_CASM3C assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_LDLR is an assay component measured in the BSK_CASM3C assay. It measures LDLR antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_MCP1 is an assay component measured in the BSK_CASM3C assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_MCSF is an assay component measured in the BSK_CASM3C assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_MIG is an assay component measured in the BSK_CASM3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_Proliferation is an assay component measured in the BSK_CASM3C assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", "BSK_CASM3C_SAA is an assay component measured in the BSK_CASM3C assay. It measures SAA antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_SRB is an assay component measured in the BSK_CASM3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_CASM3C_Thrombomodulin is an assay component measured in the BSK_CASM3C assay. It measures Thrombomodulin antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_TissueFactor is an assay component measured in the BSK_CASM3C assay. It measures Tissue Factor antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_uPAR is an assay component measured in the BSK_CASM3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_VCAM1 is an assay component measured in the BSK_CASM3C assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_CollagenIII is an assay component measured in the BSK_hDFCGF assay. It measures Collagen antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_EGFR is an assay component measured in the BSK_hDFCGF assay. It measures EGFR antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_IL8 is an assay component measured in the BSK_hDFCGF assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_IP10 is an assay component measured in the BSK_hDFCGF assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_MCSF is an assay component measured in the BSK_hDFCGF assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_MIG is an assay component measured in the BSK_hDFCGF assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_MMP1 is an assay component measured in the BSK_hDFCGF assay. It measures MMP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_PAI1 is an assay component measured in the BSK_hDFCGF assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_Proliferation is an assay component measured in the BSK_hDFCGF assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", "BSK_hDFCGF_SRB is an assay component measured in the BSK_hDFCGF assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_hDFCGF_TIMP1 is an assay component measured in the BSK_hDFCGF assay. It measures TIMP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_VCAM1 is an assay component measured in the BSK_hDFCGF assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_KF3CT_ICAM1 is an assay component measured in the BSK_KF3CT assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_KF3CT_IL1a is an assay component measured in the BSK_KF3CT assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", "BSK_KF3CT_IP10 is an assay component measured in the BSK_KF3CT assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", "BSK_KF3CT_MCP1 is an assay component measured in the BSK_KF3CT assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_KF3CT_MMP9 is an assay component measured in the BSK_KF3CT assay. It measures MMP-9 antibody related to regulation of gene expression using ELISA technology.", "BSK_KF3CT_SRB is an assay component measured in the BSK_KF3CT assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_KF3CT_TIMP2 is an assay component measured in the BSK_KF3CT assay. It measures TIMP-2 antibody related to regulation of gene expression using ELISA technology.", "BSK_KF3CT_uPA is an assay component measured in the BSK_KF3CT assay. It measures uPA antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_CD40 is an assay component measured in the BSK_LPS assay. It measures CD40 antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_Eselectin is an assay component measured in the BSK_LPS assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_IL1a is an assay component measured in the BSK_LPS assay. It measures IL-a antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_IL8 is an assay component measured in the BSK_LPS assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_MCP1 is an assay component measured in the BSK_LPS assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_MCSF is an assay component measured in the BSK_LPS assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_PGE2 is an assay component measured in the BSK_LPS assay. It measures PGE2 antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_SRB is an assay component measured in the BSK_LPS assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_LPS_TissueFactor is an assay component measured in the BSK_LPS assay. It measures CD142 Tissue Factor antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_TNFa is an assay component measured in the BSK_LPS assay. It measures TNF-a antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_VCAM1 is an assay component measured in the BSK_LPS assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_CD38, is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", "BSK_SAg_CD40, is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", "BSK_SAg_CD69, is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", "BSK_SAg_Eselectin is an assay component measured in the BSK_SAg assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_IL8 is an assay component measured in the BSK_SAg assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_MCP1 is an assay component measured in the BSK_SAg assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_MIG is an assay component measured in the BSK_SAg assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_PBMCCytotoxicity is an assay component measured in the BSK_SAg assay. It measures Alamar blue related to cell death using Alamar Blue Reduction technology.", "BSK_SAg_Proliferation is an assay component in the BSK_SAg assay. It measures protein content, a form of viability reporter, as detected with absorbance signals by Sulforhodamine staining technology. ", "BSK_SAg_SRB is an assay component measured in the BSK_SAg assay. It measures protein content, a form of viability reporter, as detected with absorbance signals by Sulforhodamine staining technology.", "OT_AR_ARSRC1_0480, is one of one assay component(s) measured or calculated from the OT_AR_ARSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_AR_ARSRC1_0960, is one of one assay component(s) measured or calculated from the OT_AR_ARSRC1_0960 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_ER_ERaERa_0480, is one of one assay component(s) measured or calculated from the OT_ER_ERaERa_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_ER_ERaERa_1440, is one of one assay component(s) measured or calculated from the OT_ER_ERaERa_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_ER_ERaERb_0480, is one of one assay component(s) measured or calculated from the OT_ER_ERaERb_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_ER_ERaERb_1440, is one of one assay component(s) measured or calculated from the OT_ER_ERaERb_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_ER_ERbERb_0480, is one of one assay component(s) measured or calculated from the OT_ER_ERbERb_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_ER_ERbERb_1440, is one of one assay component(s) measured or calculated from the OT_ER_ERbERb_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_ERa_GFPERaERE_0120, is one of one assay component(s) measured or calculated from the OT_ERa_GFPERaERE_0120 assay. It is designed to make measurements of fluorescent protein induction, a form of inducible reporter, as detected with optical microscopy: fluorescence microscopy signals by Microscopy technology.", "OT_ERa_GFPERaERE_0480, is one of one assay component(s) measured or calculated from the OT_ERa_GFPERaERE_0480 assay. It is designed to make measurements of fluorescent protein induction, a form of inducible reporter, as detected with optical microscopy: fluorescence microscopy signals by Microscopy technology.", "OT_FXR_FXRSRC1_0480, is one of one assay component(s) measured or calculated from the OT_FXR_FXRSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_FXR_FXRSRC1_1440, is one of one assay component(s) measured or calculated from the OT_FXR_FXRSRC1_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_NURR1_NURR1RXRa_0480, is one of one assay component(s) measured or calculated from the OT_NURR1_NURR1RXRa_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_NURR1_NURR1RXRa_1440, is one of one assay component(s) measured or calculated from the OT_NURR1_NURR1RXRa_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_PPARg_PPARgSRC1_0480, is one of one assay component(s) measured or calculated from the OT_PPARg_PPARgSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_PPARg_PPARgSRC1_1440, is one of one assay component(s) measured or calculated from the OT_PPARg_PPARgSRC1_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "TOX21_AR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", "TOX21_AR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_AR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_AR_LUC_MDAKB2_Agonist, is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAkb2_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881, is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_Aromatase_Inhibition, is one of one assay component(s) measured or calculated from the TOX21_Aromatase_Inhibition assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_Aromatase_Inhibition_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ELG1_LUC_Agonist, is one of one assay component(s) measured or calculated from the TOX21_ELG1_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_ELG1_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ERa_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity.", "TOX21_ERa_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_ERa_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ERa_LUC_VM7_Agonist, is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_GR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity.", "TOX21_GR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_GR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_MMP_ratio, is one of 2 assay component(s) measured or calculated from the TOX21_MMP assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by homogenous mitochondrial membrane potential assay technology.", "TOX21_PPARg_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity..", "TOX21_TR_LUC_GH3_Antagonist, is one of one assay component(s) measured or calculated from the TOX21_TR_LUC_GH3_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_TR_LUC_GH3_Antagonist_viability is an assay readout measuring viability via receptor activity and designed using bioluminescence signals detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_AhR_LUC_Agonist, is one of one assay component(s) measured or calculated from the TOX21_AhR_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CALUX luciferase quantitation technology.", "TOX21_AhR_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ARE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_HSE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene  substrate used as the measure of target activity", "TOX21_p53_BLA_p1_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_FXR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_FXR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_FXR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_PPARd_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_PPARd_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_PPARd_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_PPARg_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_PPARg_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_VDR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_VDR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene reporter gene substrate used as the measure of target activity.", "TOX21_VDR_BLA_Antagonist_viability, is one of 2 assay component(s) measured or calculated from the TOX21_VDR_BLA_Antagonist assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_DT40 is an assay readout measuring cellular ATP content as a determinant of cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation", "TOX21_ARE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_HSE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_p53_BLA_p1_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_FXR_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_PPARd_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "ATG_XTT_Cytotoxicity, is one of one assay component(s) measured or calculated from the ATG_XTT_Cytotoxicity assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by XTT cytotoxicity assay technology.", "TOX21_p53_BLA_p2_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_p53_BLA_p2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_p53_BLA_p3_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_p53_BLA_p3_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_p53_BLA_p4_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1)reporter gene substrate used as the measure of target activity.", "TOX21_p53_BLA_p4_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_p53_BLA_p5_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_p53_BLA_p5_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_VDR_BLA_Agonist_viability, is one of 2 assay component(s) measured or calculated from the TOX21_VDR_BLA_Agonist assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_ESRE_BLA_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_ESRE_BLA_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_NFkB_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_NFkB_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_RAR_LUC_Agonist is one of one assay component(s) measured or calculated from the TOX21_RAR_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", "TOX21_RAR_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_RORg_LUC_CHO_Antagonist is one of one assay component(s) measured or calculated from the TOX21_RORg_LUC_CHO_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", "TOX21_RORg_LUC_CHO_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "BSK_MyoF_SRB is an assay component measured in the BSK_MyoF assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals following addition of luciferin substrate and ATP.", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_RXR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", "TOX21_RXR_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signal following addition of luciferin substrate and ATP.", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_RAR_LUC_Antagonist is one of one assay component(s) measured or calculated from the TOX21_RAR_LUC_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", "TOX21_RAR_LUC_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_H2AX_HTRF_CHO_Agonist_ratio is an assay readout measuring protein phosphorylation and designed using homogenous time resolved fluorescence between two labled antibodies. The signal is derived from the  the ratio of acceptor (d2)-conjugated antibody emission (ch2) to donor (Europium-cryptate)-conjugated antibody emission (ch1) used as the measure of target activity. ", "TOX21_AP1_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", "TOX21_AP1_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "ACEA_AR_80hr, is one of two assay component(s) measured or calculated from the ACEA_AR assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", "ACEA_ER_AUC_viability, is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", "ACEA_AR_80hr, is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", "TOX21_TSHR_HTRF_Agonist_ratio, is one of one assay component(s) measured or calculated from the TOX21_TSHR_HTRF_Agonist assay. It is designed to make measurements of TSHR agonism, with cAMP as an indicator of TSHR activation.", "TOX21_TSHR_HTRF_Antagonist_ratio, is one of one assay component(s) measured or calculated from the TOX21_TSHR_Antagonist assay. It is designed to make measurements of TSHR antagonism, with cAMP as an indicator of TSHR activation.", "TOX21_TSHR_wt_Agonist_HTRF_ratio, is one of one assay component(s) measured or calculated from the TOX21_TSHR_wt assay. It is designed to indicate background cAMP activity.", "TOX21_CAR_Agonist is one of one assay component(s) measured or calculated from the TOX21_CAR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_CAR_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_CAR_Antagonist is one of one assay component(s) measured or calculated from the TOX21_CAR_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_CAR_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ERR_Agonist is one of one assay component(s) measured or calculated from the TOX21_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_ERR_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_H2AX_HTRF_CHO_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_HDAC_Inhibition is one of one assay component(s) measured or calculated from the TOX21_HDAC_Inhibition assay. It is designed to make measurements of HDAC activity as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_HDAC_Inhibition_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_HRE_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", "TOX21_HRE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_PGC_ERR_Agonist is one of one assay component(s) measured or calculated from the TOX21_PGC_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", "TOX21_PGC_ERR_Antagonist is one of one assay component(s) measured or calculated from the TOX21_PGC_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", "TOX21_PGC_ERR_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_RT_HEK293_FLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 8 hr after exposure", "TOX21_RT_HEK293_FLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 16 hr after exposure", "TOX21_RT_HEK293_FLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 24 hr after exposure", "TOX21_RT_HEK293_FLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 32 hr after exposure", "TOX21_RT_HEK293_FLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 40 hr after exposure", "TOX21_RT_HEK293_GLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_RT_HEK293_GLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_RT_HEK293_GLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_RT_HEK293_GLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_RT_HEK293_GLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_RT_HepG2_FLO_08hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 8 hr after exposure", "TOX21_RT_HepG2_FLO_16hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 16 hr after exposure", "TOX21_RT_HepG2_FLO_24hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 24 hr after exposure", "TOX21_RT_HepG2_FLO_32hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 32 hr after exposure", "TOX21_RT_HepG2_FLO_40hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 40 hr after exposure", "TOX21_RT_HEPG2_GLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_RT_HEPG2_GLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_RT_HEPG2_GLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_RT_HEPG2_GLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_SHH_3T3_GLI3_Agonist is one of one assay component(s) measured or calculated from the TOX21_SHH_3T3_GLI3_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_SHH_3T3_GLI3_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_SHH_3T3_GLI3_Antagonist is one of one assay component(s) measured or calculated from the TOX21_SHH_3T3_GLI3_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_SHH_3T3_GLI3_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ERb_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", "TOX21_ERb_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ERb_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", "TOX21_ERb_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_PR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_PR_BLA_Agonist_viability is a component of the TOX21_PR_BLA_Agonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_PR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_PR_BLA_Antagonist_viability is a component of the TOX21_PR_BLA_Antagonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_DT40_100 is an assay readout measuring cellular ATP content as a determinant of cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation", "TOX21_DT40_657 is an assay readout measuring cellular ATP content as a determinant of cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_RT_HEPG2_GLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_PXR_viability is a component of the TOX21_PXR assay. This component measures cell viability using the CellTiter-Fluor assay system.", "TOX21_PXR_agonist is one of one assay component(s) measured or calculated from the TOX21_PXR  assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_TRHR_HEK293_Agonist is one of 2 assay components measured in the TOX21_TRHR_HEK293 assay. It is designed to make measurements of intracellular calcium, a form of biochemical reporter, as detected with Fluorescence intensity signals by FDSS 7000EX kinetic plate reader technology.", "TOX21_TRHR_HEK293_Antagonist is one of 2 assay components measured in the TOX21_TRHR_HEK293 assay. It is designed to make measurements of intracellular calcium, a form of biochemical reporter, as detected with Fluorescence intensity signals by FDSS 7000EX kinetic plate reader technology.", "TOX21_CASP3_HEPG2 is a component of the TOX21_CASP3_HEPG2 assay. This component measures caspase activity using the Caspase-Glo 3/7 assay system.", "TOX21_CASP3_HEPG2_viability is a component of the TOX21_CASP3_HEPG2 assay. This component measures cell viability using the CellTiter-Fluor assay system.", "TOX21_CASP3_CHO is a component of the TOX21_CASP3_CHO assay. This component measures caspase activity using the Caspase-Glo 3/7 assay system.", "TOX21_CASP3_CHO_viability is a component of the TOX21_CASP3_CHO assay. This component measures cell viability using the CellTiter-Fluor assay system.", "TOX21_SBE_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_SBE_BLA_Antagonist_viability is a component of the TOX21_SBE_BLA_Antagonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_SBE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_SBE_BLA_Agonist_viability is a component of the TOX21_SBE_BLA_Agonist assay. This component measures cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of red fluorescence localized in the nucleolar region of the cell nucleus as detected with high-content fluorescent imaging.", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of red fluorescence localized in the nucleolar region of the cell nucleus as detected with high-content fluorescent imaging.", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of the ratio of red fluorescence localized in the nucleolar region of the cell nucleus to red fluorescence localized in the cytoplasm as detected with high-content fluorescent imaging.", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of the ratio of red fluorescence localized in the nucleolar region of the cell nucleus to red fluorescence localized in the cytoplasm as detected with high-content fluorescent imaging.", "One of seven assay components measured from the CCTE_Harrill_HTTr_Viability assay. This was part of a full screening experiment. This is a cell-based assay that evaluates cell viability in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate membrane integrity using propidium iodide dye exclusion. Measurements are taken at 6 hours after chemical dosing in 384-well format.", "One of seven assay components measured from the CCTE_Harrill_HTTr_Apoptosis assay. This was part of a full screening experiment. This is a cell-based assay that evaluates apoptosis in MCF-7 cells cultured in DMEM + 10% fetal bovine serum. High content imaging is used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent. Measurements are taken at 6 hours after chemical dosing in 384-well format.", "BSK_BF4T_SRB is an assay component measured in the BSK_BF4T assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_IMphg_SRB is an assay component measured in the BSK_IMphg assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_IMphg_SRB.Mphg is an assay component measured in the BSK_IMphg assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology."], "assay_component_target_desc": ["Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", "Hoechst-33342 dye is used as a stain for DNA to understand viability in the system.", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element AhRE, which is responsive to the endogenous human aryl hydrocarbon receptor [GeneSymbol:AHR | GeneID:196 | Uniprot_SwissProt_Accession:P35869].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-1, which is responsive to the endogenous human FBJ murine osteosarcoma viral oncogene homolog and jun proto-oncogene [GeneSymbol:FOS & JUN | GeneID:2353 & 3725 | Uniprot_SwissProt_Accession:P01100 & P05412].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-2, which is responsive to the endogenous human transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) and transcription factor AP-2 beta (activating enhancer binding protein 2 beta) and transcription factor AP-2 delta (activating enhancer binding protein 2 delta) [GeneSymbol:TFAP2A & TFAP2B & TFAP2D | GeneID:7020 & 7021 & 83741 | Uniprot_SwissProt_Accession:P05549 & Q92481 & Q7Z6R9].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element BRE, which is responsive to the endogenous human SMAD family member 1 [GeneSymbol:SMAD1 | GeneID:4086 | Uniprot_SwissProt_Accession:Q15797].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene C/EBP, which is responsive to the endogenous human CCAAT/enhancer binding protein (C/EBP), beta [GeneSymbol:CEBPB | GeneID:1051 | Uniprot_SwissProt_Accession:P17676].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element CRE, which is responsive to the endogenous human cAMP responsive element binding protein 3 [GeneSymbol:CREB3 | GeneID:10488 | Uniprot_SwissProt_Accession:O43889].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element LXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 2 and nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H2 & NR1H3 | GeneID:7376 & 10062 | Uniprot_SwissProt_Accession:P55055 & Q13133].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RARE, which is responsive to the endogenous human retinoic acid receptor, alpha and retinoic acid receptor, beta and retinoic acid receptor, gamma [GeneSymbol:RARA & RARB & RARG | GeneID:5914 & 5915 & 5916 | Uniprot_SwissProt_Accession:P10276 & P10826 & P13631].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ebox, which is responsive to the endogenous human upstream transcription factor 1 [GeneSymbol:USF1 | GeneID:7391 | Uniprot_SwissProt_Accession:P22415].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene E2F, which is responsive to the endogenous human E2F transcription factor 1 [GeneSymbol:E2F1 | GeneID:1869 | Uniprot_SwissProt_Accession:Q01094].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene EGR, which is responsive to the endogenous human early growth response 1 [GeneSymbol:EGR1 | GeneID:1958 | Uniprot_SwissProt_Accession:P18146].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ERE, which is responsive to the endogenous human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ets, which is responsive to the endogenous human v-ets avian erythroblastosis virus E26 oncogene homolog 1 [GeneSymbol:ETS1 | GeneID:2113 | Uniprot_SwissProt_Accession:P14921].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxA, which is responsive to the endogenous human forkhead box A2 [GeneSymbol:FOXA2 | GeneID:3170 | Uniprot_SwissProt_Accession:Q9Y261].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxO, which is responsive to the endogenous human forkhead box O1 and forkhead box O3 [GeneSymbol:FOXO1 & FOXO3 | GeneID:2308 & 2309 | Uniprot_SwissProt_Accession:Q12778 & O43524].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GATA, which is responsive to the endogenous human GATA binding protein 1 (globin transcription factor 1) [GeneSymbol:GATA1 | GeneID:2623 | Uniprot_SwissProt_Accession:P15976].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GLI, which is responsive to the endogenous human GLI family zinc finger 1 [GeneSymbol:GLI1 | GeneID:2735 | Uniprot_SwissProt_Accession:P08151].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element GRE, which is responsive to the endogenous human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HIF1a, which is responsive to the endogenous human hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) [GeneSymbol:HIF1A | GeneID:3091 | Uniprot_SwissProt_Accession:Q16665].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HNF6, which is responsive to the endogenous human one cut homeobox 1 [GeneSymbol:ONECUT1 | GeneID:3175 | Uniprot_SwissProt_Accession:Q9UBC0].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HSE, which is responsive to the endogenous human heat shock transcription factor 1 [GeneSymbol:HSF1 | GeneID:3297 | Uniprot_SwissProt_Accession:Q00613].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene IR1, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ISRE, which is responsive to the endogenous human interferon regulatory factor 1 [GeneSymbol:IRF1 | GeneID:3659 | Uniprot_SwissProt_Accession:P10914].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element MRE, which is responsive to the endogenous human metal-regulatory transcription factor 1 [GeneSymbol:MTF1 | GeneID:4520 | Uniprot_SwissProt_Accession:Q14872].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myb, which is responsive to the endogenous human v-myb avian myeloblastosis viral oncogene homolog [GeneSymbol:MYB | GeneID:4602 | Uniprot_SwissProt_Accession:P10242].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myc, which is responsive to the endogenous human v-myc avian myelocytomatosis viral oncogene homolog [GeneSymbol:MYC | GeneID:4609 | Uniprot_SwissProt_Accession:P01106].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NF-kB, which is responsive to the endogenous human nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 [GeneSymbol:NFKB1 | GeneID:4790 | Uniprot_SwissProt_Accession:P19838].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NFI, which is responsive to the endogenous human nuclear factor I/A [GeneSymbol:NFIA | GeneID:4774 | Uniprot_SwissProt_Accession:Q12857].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NRF1, which is responsive to the endogenous human nuclear respiratory factor 1 [GeneSymbol:NRF1 | GeneID:4899 | Uniprot_SwissProt_Accession:Q16656].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ARE, which is responsive to the endogenous human nuclear factor, erythroid 2-like 2 [GeneSymbol:NFE2L2 | GeneID:4780 | Uniprot_SwissProt_Accession:Q16236].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Oct, which is responsive to the endogenous human POU class 2 homeobox 1 [GeneSymbol:POU2F1 | GeneID:5451 | Uniprot_SwissProt_Accession:P14859].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene p53, which is responsive to the endogenous human tumor protein p53 [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Pax, which is responsive to the endogenous human paired box 6 [GeneSymbol:PAX6 | GeneID:5080 | Uniprot_SwissProt_Accession:P26367].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene PBREM, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PPRE, which is responsive to the endogenous human peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor delta and peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARA & PPARD & PPARG | GeneID:5465 & 5467 & 5468 | Uniprot_SwissProt_Accession:Q07869 & Q03181 & P37231].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RORE, which is responsive to the endogenous human RAR-related orphan receptor A and RAR-related orphan receptor B and RAR-related orphan receptor C [GeneSymbol:RORA & RORB & RORC | GeneID:6095 & 6096 & 6097 | Uniprot_SwissProt_Accession:P35398 & Q92753 & P51449].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SOX, which is responsive to the endogenous human SRY (sex determining region Y)-box 1 [GeneSymbol:SOX1 | GeneID:6656 | Uniprot_SwissProt_Accession:O00570].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Sp1, which is responsive to the endogenous human Sp1 transcription factor [GeneSymbol:SP1 | GeneID:6667 | Uniprot_SwissProt_Accession:P08047].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SREBP, which is responsive to the endogenous human sterol regulatory element binding transcription factor 1 [GeneSymbol:SREBF1 | GeneID:6720 | Uniprot_SwissProt_Accession:P36956].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene STAT, which is responsive to the endogenous human signal transducer and activator of transcription 3 (acute-phase response factor) [GeneSymbol:STAT3 | GeneID:6774 | Uniprot_SwissProt_Accession:P40763].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TGF, which is responsive to the endogenous human transforming growth factor, beta 1 [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element VDRE, which is responsive to the endogenous human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Xbp1, which is responsive to the endogenous human X-box binding protein 1 [GeneSymbol:XBP1 | GeneID:7494 | Uniprot_SwissProt_Accession:P17861].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-AR, also known as human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-CAR, also known as human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERa, also known as human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERRa, also known as human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101 | Uniprot_SwissProt_Accession:P11474].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERRg, also known as human estrogen-related receptor gamma [GeneSymbol:ESRRG | GeneID:2104 | Uniprot_SwissProt_Accession:P62508].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-FXR, also known as human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-GR, also known as human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-HNF4a, also known as human hepatocyte nuclear factor 4, alpha [GeneSymbol:HNF4A | GeneID:3172 | Uniprot_SwissProt_Accession:P41235].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRa, also known as human nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H3 | GeneID:10062 | Uniprot_SwissProt_Accession:Q13133].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRb, also known as human nuclear receptor subfamily 1, group H, member 2 [GeneSymbol:NR1H2 | GeneID:7376 | Uniprot_SwissProt_Accession:P55055].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-NURR1, also known as human nuclear receptor subfamily 4, group A, member 2 [GeneSymbol:NR4A2 | GeneID:4929 | Uniprot_SwissProt_Accession:P43354].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARa, also known as human peroxisome proliferator-activated receptor alpha [GeneSymbol:PPARA | GeneID:5465 | Uniprot_SwissProt_Accession:Q07869].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARd, also known as human peroxisome proliferator-activated receptor delta [GeneSymbol:PPARD | GeneID:5467 | Uniprot_SwissProt_Accession:Q03181].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARg, also known as human peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARG | GeneID:5468 | Uniprot_SwissProt_Accession:P37231].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PXR, also known as human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARa, also known as human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARb, also known as human retinoic acid receptor, beta [GeneSymbol:RARB | GeneID:5915 | Uniprot_SwissProt_Accession:P10826].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARg, also known as human retinoic acid receptor, gamma [GeneSymbol:RARG | GeneID:5916 | Uniprot_SwissProt_Accession:P13631].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RORb, also known as human RAR-related orphan receptor B [GeneSymbol:RORB | GeneID:6096 | Uniprot_SwissProt_Accession:Q92753].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RORg, also known as human RAR-related orphan receptor C [GeneSymbol:RORC | GeneID:6097 | Uniprot_SwissProt_Accession:P51449].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRa, also known as human retinoid X receptor, alpha [GeneSymbol:RXRA | GeneID:6256 | Uniprot_SwissProt_Accession:P19793].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRb, also known as human retinoid X receptor, beta [GeneSymbol:RXRB | GeneID:6257 | Uniprot_SwissProt_Accession:P28702].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-THRa, also known as human thyroid hormone receptor, alpha [GeneSymbol:THRA | GeneID:7067 | Uniprot_SwissProt_Accession:P10827].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-VDR, also known as human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473].", "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", "HLA-DR antibody is used to tag and quantify the level of major histocompatibility complex, class II, DR alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:HLA-DRA | GeneID:3122 | Uniprot_SwissProt_Accession:P01903].", "ICAM-1 antibody is used to tag and quantify the level of intercellular adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:ICAM1 | GeneID:3383 | Uniprot_SwissProt_Accession:P05362].", "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", "Proliferation in the 3C system is a measure of endothelial cell profliferation which is important to the process of wound healing and angiogensis.", "SRB in the 3C system is a measure of the total protein content of venular endothelial cells.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", "Thrombomodulin antibody is used to tag and quantify the level of thrombomodulin protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:THBD | GeneID:7056 | Uniprot_SwissProt_Accession:P07204].", "Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726].", "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", "Eotaxin-3 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 26 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:CCL26 | GeneID:10344 | Uniprot_SwissProt_Accession:Q9Y258].", "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", "P-Selectin antibody is used to tag and quantify the level of selectin P (granule membrane protein 140kDa, antigen CD62) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:SELP | GeneID:6403 | Uniprot_SwissProt_Accession:P16109].", "SRB in the 4H system is a measure of the total protein content of venular endothelial cells.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", "VEGFRII antibody is used to tag and quantify the level of kinase insert domain receptor (a type III receptor tyrosine kinase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:KDR | GeneID:3791 | Uniprot_SwissProt_Accession:P35968].", "IL-1a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", "MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956].", "PAI-1 antibody is used to tag and quantify the level of serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SERPINE1 | GeneID:5054 | Uniprot_SwissProt_Accession:P05121].", "SRB in the BE3C system is a measure of the total protein content of bronchial epithelial cells.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", "tPA antibody is used to tag and quantify the level of plasminogen activator, tissue protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAT | GeneID:5327 | Uniprot_SwissProt_Accession:P00750].", "uPA antibody is used to tag and quantify the level of plasminogen activator, urokinase protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAU | GeneID:5328 | Uniprot_SwissProt_Accession:P00749].", "IL-6 antibody is used to tag and quantify the level of interleukin 6 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:IL6 | GeneID:3569 | Uniprot_SwissProt_Accession:P05231].", "LDLR antibody is used to tag and quantify the level of low density lipoprotein receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:LDLR | GeneID:3949 | Uniprot_SwissProt_Accession:P01130].", "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", "Proliferation in the CASM3C system is a measure of coronary artery smooth muscle cell proliferation which is important to the process of vasacular biology and restenosis.", "Serum Amyloid A (SAA) is a member of the apolipoprotein family that is an acute phase reactant.  SAA is categorized as an inflammation-related activity in the CASM3C system modeling Th1 vascular smooth muscle inflammation. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SAA1 | GeneID:6288 | Uniprot_SwissProt_Accession:P0DJI8].", "SRB in the CASM3C system is a measure of the total protein content of coronary artery smooth muscle cells.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", "Collagen antibody is used to tag and quantify the level of collagen, type III, alpha 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:COL3A1 | GeneID:1281 | Uniprot_SwissProt_Accession:P02461].", "EGFR antibody is used to tag and quantify the level of epidermal growth factor receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:EGFR | GeneID:1956 | Uniprot_SwissProt_Accession:P00533].", "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", "MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956].", "PAI-1 antibody is used to tag and quantify the level of serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:SERPINE1 | GeneID:5054 | Uniprot_SwissProt_Accession:P05121].", "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and growth factors.", "TIMP-1 antibody is used to tag and quantify the level of TIMP metallopeptidase inhibitor 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:TIMP1 | GeneID:7076 | Uniprot_SwissProt_Accession:P01033].", "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", "ICAM-1 antibody is used to tag and quantify the level of intercellular adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:ICAM1 | GeneID:3383 | Uniprot_SwissProt_Accession:P05362].", "IL-1a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", "MMP-9 antibody is used to tag and quantify the level of matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:MMP9 | GeneID:4318 | Uniprot_SwissProt_Accession:P14780].", "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and TGFb.", "TIMP-2 antibody is used to tag and quantify the level of TIMP metallopeptidase inhibitor 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:TIMP2 | GeneID:7077 | Uniprot_SwissProt_Accession:Q96MC4].", "uPA antibody is used to tag and quantify the level of plasminogen activator, urokinase protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:PLAU | GeneID:5328 | Uniprot_SwissProt_Accession:P00749].", "CD40 antibody is used to tag and quantify the level of CD40 molecule, TNF receptor superfamily member 5 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CD40 | GeneID:958 | Uniprot_SwissProt_Accession:P25942].", "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", "IL-a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", "PGE2 antibody is used to tag and quantify the level of prostaglandin E receptor 2 (subtype EP2), 53kDa protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:PTGER2 | GeneID:5732 | Uniprot_SwissProt_Accession:P43116].", "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator.", "CD142 Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726].", "TNF-a antibody is used to tag and quantify the level of tumor necrosis factor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:TNF | GeneID:7124 | Uniprot_SwissProt_Accession:P01375].", "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", "CD38 antibody is used to tag and quantify the level of CD38 molecule protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD38 | GeneID:952 | Uniprot_SwissProt_Accession:P28907].", "CD40 antibody is used to tag and quantify the level of CD40 molecule, TNF receptor superfamily member 5 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD40 | GeneID:958 | Uniprot_SwissProt_Accession:P25942].", "CD69 antibody is used to tag and quantify the level of CD69 molecule protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD69 | GeneID:969 | Uniprot_SwissProt_Accession:Q07108].", "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [Alamar blue] are correlated to the viability of the cells in the system.", "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation.", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human androgen receptor and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:AR & SRC | GeneID:367 & 6714 | Uniprot_SwissProt_Accession:P10275 & P12931].", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 and estrogen receptor 2 (ER beta) [GeneSymbol:ESR1 & ESR2 | GeneID:2099 & 2100 | Uniprot_SwissProt_Accession:P03372 & Q92731].", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 2 (ER beta) [GeneSymbol:ESR2 | GeneID:2100 | Uniprot_SwissProt_Accession:Q92731].", "Changes to optical microscopy: fluorescence microscopy signals produced from the fluorescent protein induction are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human SRC proto-oncogene, non-receptor tyrosine kinase and nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:SRC & NR1H4 | GeneID:6714 & 9971 | Uniprot_SwissProt_Accession:P12931 & Q96RI1].", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human nuclear receptor subfamily 4, group A, member 2 and retinoid X receptor, alpha [GeneSymbol:NR4A2 & RXRA | GeneID:4929 & 6256 | Uniprot_SwissProt_Accession:P43354 & P19793].", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human peroxisome proliferator-activated receptor gamma and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:PPARG & SRC | GeneID:5468 & 6714 | Uniprot_SwissProt_Accession:P37231 & P12931].", "TOX21_AR_BLA_Agonist_ratio was designed to  target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of R1881 ", "TOX21_AR_BLA_Antagonist_ratio was designed to  target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of Cyproterone acetate ", "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", "Androgen receptor (AR) is an important member of the nuclear receptor family. Its signaling plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Considerable attention has been given in the past decades to develop methods to study and screen for the environmental chemicals that have the potential to interfere with metabolic homeostasis, reproduction, developmental and behavioral functions. Therefore AR binding assay for screening androgen antagonists can be used to identify potential endocrine disruptors. Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to modulation of the human cytochrome P450, family 19, subfamily A, polypeptide 1 [GeneSymbol:CYP19A1 | GeneID:1588 | Uniprot_SwissProt_Accession:P11511].", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human ATPase family, AAA domain containing 5 [GeneSymbol:ATAD5 | GeneID:79915 | Uniprot_SwissProt_Accession:Q96QE3].", "TOX21_ERa_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 17b-estradiol", "TOX21_ERa_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 4-hydroxytamoxifen", "TOX21_ERa_LUC_VM7_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372] using a positive control of 4-hydroxytamoxifen", "TOX21_GR_BLA_Agonist_ratio was designed to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Dexamethasone", "TOX21_GR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Mifepristone", "Mito-MPS is used as a stain for the membrane potential of the mitochondria.", "TOX21_PPARg_BLA_Agonist_ratio was designed to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of Rosiglitazone", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", "Changes to bioluminescence signals produced from the luciferase induction are indicative of agonist activity regulated by the receptor function and kinetics for the human aryl hydrocarbon receptor [GeneSymbol:AHR | GeneID:196 | Uniprot_SwissProt_Accession:P35869].", "TOX21_ARE_BLA_Agonist_ratio was designed to  target transcription factor activity, specifically mapping to NFE2L2 gene(s) using a positive control of Beta-Naphthoflavone", "TOX21_HSE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to HSF1 gene(s) using a positive control of 17-AAG", "TOX21_p53_BLA_p1_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", "TOX21_FXR_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Chenodeoxycholic acid", "TOX21_FXR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Guggulsterone", "TOX21_PPARD_BLA_Agonist_ratio was designed to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of L-165,041", "TOX21_PPARD_BLA_Antagonist_ratio was designed to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of MK886", "TOX21_PPARg_BLA_Antagonist_ratio was designed to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of GW9662", "TOX21_VDR_BLA_Agonist_ratio was designed to measure cleaved reporter gene substrate to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Calcitriol", "TOX21_VDR_BLA_Antagonist_ratio was designed to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Tetraoctyl ammonium bromide", "TOX21_DT40 assay was designed to target cell cycle (cytotoxicity) activity at the cellular (cellular) level in isogenic wildtype cells using a positive control of tetraoctylammonium bromide. Results from the wild-type cells can be compared to TOX21_DT40_100 (aeid 2130) and TOX21_DT40_657 (aeid 2131) isogenic cell line assays which contain DNA repair enzyme deletions to detect DNA-damaging agents", "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [XTT reagent] are correlated to the viability of the mitochondria in the system.", "TOX21_p53_BLA_p2_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", "TOX21_p53_BLA_p3_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", "TOX21_p53_BLA_p4_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", "TOX21_p53_BLA_p5_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", "TOX21_ESRE_BLA_ratio was designed to target transcription factor activity, specifically mapping to ATF6 gene(s) using a positive control of 17-AAG", "TOX21_NFkB_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to NFKB1 gene(s) using a positive control of TNFa", "TOX21_RAR_LUC_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoic acid receptor alpha  [GeneSymbol:RARA]", "TOX21_RORg_LUC_CHO_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoid-related orphan receptor gamma  [GeneSymbol:NR1F3]", "SRB in the MyoF system is a measure of the total protein content of lung fibroblasts.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", "Androgen receptor (AR) is an important member of the nuclear receptor family. Its signaling plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Considerable attention has been given in the past decades to develop methods to study and screen for the environmental chemicals that have the potential to interfere with metabolic homeostasis, reproduction, developmental and behavioral functions. Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", "TOX21_RXR_BLA_Agonist_ratio was designed to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to RXRA gene(s) using a positive control of 9-cis-Retinoic acid", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] in the presence of an AR agonist. Changes are indicative of  transcriptional gene expression that may not be due to direct regulation by the human androgen receptor [GeneSymbol: NR3C4 | GeneID: NR3C4 | Uniprot_SwissProt_Accession:].", "TOX21_RAR_LUC_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoic acid receptor alpha  [GeneSymbol:RARA]", "TOX21_H2AX_HTRF_CHO_Agonist_ratio  was designed to target protein phosphorylation, specifically mapping to H2AFX gene(s) using a positive control of Etoposide", "TOX21_AP1_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to JUN gene(s) using a positive control of EGF", "TOX21_TSHR_HTRF_Agonist_ratio was designed to target  receptor activation through increased cAMP generation, specifically mapping to TSHR gene(s) using a positive control of TSH.", "TOX21_TSHR_HTRF_Antagonist_ratio was designed to target  receptor inhibition through decreased cAMP generation, specifically mapping to TSHR gene(s) using a positive control of no TSH stimulation", "TOX21_TSHR_wt_HTRF_ratio was designed to target  background cAMP generation in cells lacking TSHR", "TOX21_CAR_Agonist assay  was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human constitutive androstane receptor (CAR) [GeneSymbol:NR1I3]", "TOX21_CAR_Antagonist assay  was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human constitutive androstane receptor (CAR)  [GeneSymbol:NR1I3] stimulated with CITCO", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "TOX21_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101|.", "TOX21_HDAC_Inhibition was designed to target enzymatic activity specifically mapping to HDAC1 gene(s) using a positive control of Trichostatin A", "TOX21_HRE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to HIF1A gene(s) using a positive control of Cobalt(II)chloride hexahydrate", "TOX21_PGC_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha  [GeneSymbol:ESRRA | GeneID:2101| in the presence of PGC1a expression", "TOX21_PGC_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101|in the presence of PGC1a expression", "TOX21_RT_HEK293_FLO_08hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HEK293_FLO_16hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HEK293_FLO_24hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HEK293_FLO_32hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HEK293_FLO_40hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HEK293_GLO_08hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_RT_HEK293_GLO_16hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_RT_HEK293_GLO_24hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_RT_HEK293_GLO_32hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_RT_HEK293_GLO_40hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_RT_HepG2_FLO_08hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HepG2_FLO_16hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HepG2_FLO_24hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HepG2_FLO_32hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HepG2_FLO_40hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HEPG2_GLO_08hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_RT_HEPG2_GLO_16hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_RT_HEPG2_GLO_32hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_RT_HEPG2_GLO_40hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_SHH_3T3_GLI3_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by Gli3, part of the sonic hedgehog (Shh) pathway", "TOX21_SHH_3T3_GLI3_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to antagonism  of Gli3 activation using conditioned medium, part of the sonic hedgehog (Shh) pathway", "TOX21_ERb_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 4-hydroxytamoxifen", "TOX21_ERb_BLA_Agonist_ch2 was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 17b-estradiol", "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", "TOX21_DT40_100 assay was designed to target cell cycle (cytotoxicity) activity at the cellular (cellular) level, specifically mapping to Ku70 and Rad54 gene(s) using a positive control of tetraoctylammonium bromide. The DT40_100 cells have Ku70 and Rad54 gene deletions (-/-) which are involved in reparing chromosomal breaks. Results should be compared to the isogenic wild-type cells (DT40; aeid 1124 ) and Rev3(-/-) (DT40_657; aeid 2131) to evaluate potential DNA-damaging agents", "TOX21_DT40_657 assay was designed to target cell cycle (cytotoxicity) activity at the cellular (cellular) level, specifically mapping to Rev3 gene(s) using a positive control of tetraoctylammonium bromide. The DT40_657 cells have Rev3 gene deletions (-/-) which is involved in DNA repair. Results should be compared to the isogenic wild-type cells (DT40; aeid 1124 ) and Ku70/Rad54 (DT40_100; aeid 2130) to evaluate potential DNA-damaging agents. ", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] in the presence of an ER antagonist. Changes are indicative of  transcriptional gene expression that may not be due to direct regulation by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "TOX21_RT_HEPG2_GLO_24hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "The human pregnane X receptor (hPXR) regulates the expression of several drug metabolizing enzymes and induction of these proteins is a major mechanism for developing drug resistance in cancer. One such key enzyme catalyzing the drug metabolism is cytochrome P450 3A4 (CYP3A4). Changes in CYP3A4 expression affect drug metabolism, thereby reducing the therapeutic efficacy and altering toxicological response to a drug and which finally causes adverse drug interaction.", "The human pregnane X receptor (hPXR) regulates the expression of several drug metabolizing enzymes and induction of these proteins is a major mechanism for developing drug resistance in cancer. One such key enzyme catalyzing the drug metabolism is cytochrome P450 3A4 (CYP3A4). Changes in CYP3A4 expression affect drug metabolism, thereby reducing the therapeutic efficacy and altering toxicological response to a drug and which finally causes adverse drug interaction.\u00a0", "Thyrotropin-releasing hormone (TRH) receptor (TRHR) is a G-protein-coupled receptor which binds the tripeptide thyrotropin releasing hormone. TRHR is found in the brain and, when bound by TRH, acts (through phospholipase C) to increase intracellular inositol trisphosphate. It plays a crucial role in the anterior pituitary where it controls the synthesis and secretion of thyroid stimulating hormone and prolactin. Intracellular calcium is measured as an indicator of Gq-coupled human thyrotropin-releasing hormone receptor (TRHR) activation using fluorescent detection in a TRHR-Hek293 cell-based assay. Activation of this GPCR is indicated by increased intracellular calcium as measured in this cell-based fluorescent reporter assay.", "Thyrotropin-releasing hormone (TRH) receptor (TRHR) is a G-protein-coupled receptor which binds the tripeptide thyrotropin releasing hormone. TRHR is found in the brain and, when bound by TRH, acts (through phospholipase C) to increase intracellular inositol trisphosphate. It plays a crucial role in the anterior pituitary where it controls the synthesis and secretion of thyroid stimulating hormone and prolactin. Inactivation of this GPCR is indicated by decreased intracellular calcium as measured in this cell-based fluorescent assay.", "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection.", "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection. ", "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", "Loss of DHT-induced red fluorescence in nucleolar region of the cell nucleus is consistent with antagonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", "Increased red fluorescence in nucleolar region of the cell nucleus is consistent with agonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", "Decrease of the ratio of DHT-induced red fluorescence in nucleolar region of the cell nucleus to the red fluorescence localized in the cytoplasm is consistent with antagonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", "Increased ratio of DHT-induced red fluorescence in nucleolar region of the cell nucleus to the red fluorescence localized in the cytoplasm is consistent with agonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", "propidium iodide is membrane impermeant and binds to DNA in dead/dying cells.", "Caspase 3/7 kit", "SRB in the BF4T system is a measure of the total protein content of bronchial epithelial cells and dermal fibroblasts.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", "SRB in the lMphg system is a measure of the total protein content of venular endothelial cells and macrophages.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", "SRB-Mphg in the lMphg system is a measure of the total protein content of macrophages alone.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells."], "parameter_readout_type": ["single", "multiple", "multiplexed"], "assay_design_type": ["growth reporter", "viability reporter", "inducible reporter", "binding reporter", "membrane potential reporter", "background reporter", "biochemical reporter", "apoptosis reporter"], "assay_design_type_sub": ["real-time cell-growth kinetics", "cell number", "mRNA induction", "immunoassay: elisa", "protein content", "dehydrogenase activity determination", "protein fragment complementation assay", "fluorescent protein induction", "beta lactamase induction", "ATP content", "luciferase induction", "dye binding", "cAMP measurement", "dead cells", "metabolic activity", "artifact detection", "living cells", "intracellular calcium", "caspase activity", "protein-protein binding", "membrane impermeable stain for DNA", "Caspase 3/7 activity"], "biological_process_target": ["cell proliferation", "cell death", "regulation of transcription factor activity", "regulation of gene expression", "protein stabilization", "mitochondrial depolarization", "regulation of DNA repair", "artifact detection", "cytotoxicity", "receptor activation", "apoptosis", "receptor binding", "cell cycle"], "detection_technology_type": ["Label Free Technology", "Fluorescence", "Spectrophotometry", "Microscopy", "Luminescence"], "detection_technology_type_sub": ["Electrical Sensor: Impedance", "Fluorescence intensity", "Absorbance", "Optical microscopy: Fluorescence microscopy", "Bioluminescence"], "detection_technology": ["RT-CES", "HCS Fluorescent Imaging", "RT-PCR and Capillary electrophoresis", "ELISA", "Sulforhodamine staining", "Alamar Blue Reduction", "Protein-fragment Complementation", "Microscopy", "GAL4 b-lactamase reporter gene", "CellTiter-Glo Luciferase-coupled ATP quantitation", "homogenous mitochondrial membrane potential assay", "CALUX luciferase quantitation", "XTT cytotoxicity assay", "Homogeneous Time Resolved Fluorescence", "Fluorescence emission", "RealTime-Glo MT Cell Viability Assay", "Cell Titer Fluor assay", "FDSS 7000EX kinetic plate reader\u00a0", "Caspase-Glo 3/7", "Cell Titer Fluor assay "], "signal_direction_type": ["both", "gain", "loss"], "key_assay_reagent_type": ["NA", "stain", "inducer", "antibody", "substrate", "chemical"], "key_assay_reagent": ["NA", "Hoechst-33342 dye", "AhRE RTU", "AP-1 RTU", "AP-2 RTU", "BRE RTU", "C/EBP RTU", "CRE RTU", "LXRE RTU", "RARE RTU", "Ebox RTU", "E2F RTU", "EGR RTU", "ERE RTU", "Ets RTU", "FoxA RTU", "FoxO RTU", "GATA RTU", "GLI RTU", "GRE RTU", "HIF1a RTU", "HNF6 RTU", "HSE RTU", "IR1 RTU", "ISRE RTU", "MRE RTU", "Myb RTU", "Myc RTU", "NF-kB RTU", "NFI RTU", "NRF1 RTU", "ARE RTU", "Oct RTU", "p53 RTU", "Pax RTU", "PBREM RTU", "PPRE RTU", "PXRE RTU", "RORE RTU", "SOX RTU", "Sp1 RTU", "SREBP RTU", "STAT RTU", "TGF RTU", "VDRE RTU", "Xbp1 RTU", "GAL4-AR RTU", "GAL4-CAR RTU", "GAL4-ERa RTU", "GAL4-ERRa RTU", "GAL4-ERRg RTU", "GAL4-FXR RTU", "GAL4-GR RTU", "GAL4-HNF4a RTU", "GAL4-LXRa RTU", "GAL4-LXRb RTU", "GAL4-NURR1 RTU", "GAL4-PPARa RTU", "GAL4-PPARd RTU", "GAL4-PPARg RTU", "GAL4-PXR RTU", "GAL4-RARa RTU", "GAL4-RARb RTU", "GAL4-RARg RTU", "GAL4-RORb RTU", "GAL4-RORg RTU", "GAL4-RXRa RTU", "GAL4-RXRb RTU", "GAL4-THRa RTU", "GAL4-VDR RTU", "E-selectin antibody", "HLA-DR antibody", "ICAM-1 antibody", "IL-8 antibody", "MCP-1 antibody", "MIG antibody", "0.1% sulforhodamine", "Thrombomodulin antibody", "Tissue Factor antibody", "uPAR antibody", "VCAM-1 antibody", "Eotaxin-3 antibody", "P-Selectin antibody", "VEGFRII antibody", "IL-1a antibody", "IP-10 antibody", "MMP-1 antibody", "PAI-1 antibody", "tPA antibody", "uPA antibody", "IL-6 antibody", "LDLR antibody", "M-CSF antibody", "SAA antibody", "Collagen antibody", "EGFR antibody", "TIMP-1 antibody", "MMP-9 antibody", "TIMP-2 antibody", "CD40 antibody", "IL-a antibody", "PGE2 antibody", "CD142 Tissue Factor antibody", "TNF-a antibody", "CD38 antibody", "CD69 antibody", "Alamar blue", "CCF4-AM", "CellTiter-Glo", "One-Glo", "Mito-MPS", "XTT reagent", "CellTox Green", "d2-labeled cAMP", "NanoLuc/profurimazine", "CellTiter-Fluor reagent", "intracellular calcium", "Caspase-Glo 3/7 reagent", "propidium iodide", "CellEvent Caspase 3/7 Green detection reagent"], "technological_target_type": ["cellular", "dna", "rna", "protein", "chemical", "cell morphology", "chemical "], "technological_target_type_sub": ["cellular", "dna-unspecified", "mRNA", "protein-specified", "protein-unspecified", "receptor", "ATP", "enzyme", "mitochondria", "intracellular calcium", "receptor binding", "nuclear DNA", "caspase"], "aeid": [2, 25, 45, 63, 1400, 64, 1401, 65, 1402, 66, 1404, 67, 1410, 69, 1409, 70, 1412, 71, 1413, 72, 1424, 73, 1414, 74, 75, 1419, 76, 1423, 77, 1425, 78, 1426, 79, 1429, 1431, 81, 1432, 82, 1434, 83, 1437, 84, 1439, 85, 1440, 86, 1441, 91, 92, 1447, 93, 1448, 94, 1458, 95, 1457, 96, 1460, 97, 1461, 98, 1464, 99, 1465, 100, 101, 1467, 102, 1472, 103, 1474, 104, 1483, 105, 1490, 106, 1491, 107, 1492, 108, 1493, 112, 1497, 113, 1503, 114, 1505, 115, 1403, 116, 1405, 117, 1417, 1420, 119, 1422, 120, 1427, 122, 1433, 123, 1435, 125, 1443, 126, 1444, 131, 1463, 132, 1469, 133, 134, 135, 1475, 136, 1476, 137, 1477, 138, 1478, 1482, 140, 1484, 141, 1485, 142, 1486, 143, 1498, 144, 1504, 145, 146, 147, 149, 151, 152, 153, 154, 155, 157, 159, 161, 162, 163, 164, 165, 166, 167, 171, 172, 173, 175, 176, 177, 179, 180, 181, 183, 184, 185, 186, 187, 188, 189, 191, 193, 194, 195, 196, 197, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 241, 242, 243, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 259, 260, 261, 262, 263, 264, 265, 266, 267, 269, 273, 274, 275, 277, 279, 280, 281, 282, 283, 284, 285, 286, 287, 289, 290, 291, 293, 294, 295, 296, 297, 299, 300, 301, 303, 305, 306, 307, 308, 309, 310, 311, 313, 314, 315, 317, 740, 741, 742, 743, 744, 745, 746, 747, 750, 751, 753, 754, 755, 756, 757, 758, 761, 762, 763, 764, 765, 766, 767, 768, 781, 782, 785, 786, 787, 788, 789, 790, 793, 794, 795, 797, 1854, 802, 804, 805, 806, 807, 1110, 1113, 1116, 1119, 1120, 1121, 1124, 1125, 1126, 1127, 1128, 1131, 1132, 1133, 1134, 1185, 1186, 1187, 1188, 1195, 1204, 1317, 1318, 1321, 1322, 1325, 1326, 1329, 1330, 1331, 1342, 1343, 1346, 1347, 1659, 1660, 1661, 1662, 2846, 1816, 1817, 1820, 1821, 1822, 1823, 1839, 1840, 1843, 1846, 1847, 1850, 1852, 1857, 2040, 2043, 2046, 2047, 2048, 2049, 2050, 2053, 2054, 2055, 2057, 2059, 2060, 2061, 2062, 2065, 2066, 2068, 2070, 2072, 2075, 2077, 2078, 2080, 2082, 2086, 2088, 2089, 2091, 2093, 2095, 2096, 2097, 2098, 2099, 2101, 2102, 2103, 2105, 2106, 2107, 2108, 2109, 2119, 2120, 2115, 2116, 2123, 2124, 2127, 2128, 2130, 2131, 2211, 2212, 2213, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2372, 2373, 2376, 2377, 2386, 2387, 2390, 2391, 2451, 2452, 2874, 2930, 2932], "assay_component_endpoint_name": ["ACEA_ER_80hr", "APR_HepG2_CellLoss_24h_dn", "APR_HepG2_CellLoss_72h_dn", "ATG_Ahr_CIS_up", "ATG_Ahr_CIS_dn", "ATG_AP_1_CIS_up", "ATG_AP_1_CIS_dn", "ATG_AP_2_CIS_up", "ATG_AP_2_CIS_dn", "ATG_BRE_CIS_up", "ATG_BRE_CIS_dn", "ATG_C_EBP_CIS_up", "ATG_C_EBP_CIS_dn", "ATG_CRE_CIS_up", "ATG_CRE_CIS_dn", "ATG_DR4_LXR_CIS_up", "ATG_DR4_LXR_CIS_dn", "ATG_DR5_CIS_up", "ATG_DR5_CIS_dn", "ATG_E_Box_CIS_up", "ATG_E_Box_CIS_dn", "ATG_E2F_CIS_up", "ATG_E2F_CIS_dn", "ATG_EGR_CIS_up", "ATG_ERE_CIS_up", "ATG_ERE_CIS_dn", "ATG_Ets_CIS_up", "ATG_Ets_CIS_dn", "ATG_FoxA2_CIS_up", "ATG_FoxA2_CIS_dn", "ATG_FoxO_CIS_up", "ATG_FoxO_CIS_dn", "ATG_GATA_CIS_up", "ATG_GATA_CIS_dn", "ATG_GLI_CIS_dn", "ATG_GRE_CIS_up", "ATG_GRE_CIS_dn", "ATG_HIF1a_CIS_up", "ATG_HIF1a_CIS_dn", "ATG_HNF6_CIS_up", "ATG_HNF6_CIS_dn", "ATG_HSE_CIS_up", "ATG_HSE_CIS_dn", "ATG_IR1_CIS_up", "ATG_IR1_CIS_dn", "ATG_ISRE_CIS_up", "ATG_ISRE_CIS_dn", "ATG_MRE_CIS_up", "ATG_Myb_CIS_up", "ATG_Myb_CIS_dn", "ATG_Myc_CIS_up", "ATG_Myc_CIS_dn", "ATG_NF_kB_CIS_up", "ATG_NF_kB_CIS_dn", "ATG_NFI_CIS_up", "ATG_NFI_CIS_dn", "ATG_NRF1_CIS_up", "ATG_NRF1_CIS_dn", "ATG_NRF2_ARE_CIS_up", "ATG_NRF2_ARE_CIS_dn", "ATG_Oct_MLP_CIS_up", "ATG_Oct_MLP_CIS_dn", "ATG_p53_CIS_up", "ATG_p53_CIS_dn", "ATG_Pax6_CIS_up", "ATG_PBREM_CIS_up", "ATG_PBREM_CIS_dn", "ATG_PPRE_CIS_up", "ATG_PPRE_CIS_dn", "ATG_PXRE_CIS_up", "ATG_PXRE_CIS_dn", "ATG_RORE_CIS_up", "ATG_RORE_CIS_dn", "ATG_Sox_CIS_up", "ATG_Sox_CIS_dn", "ATG_Sp1_CIS_up", "ATG_Sp1_CIS_dn", "ATG_SREBP_CIS_up", "ATG_SREBP_CIS_dn", "ATG_STAT3_CIS_up", "ATG_STAT3_CIS_dn", "ATG_TGFb_CIS_up", "ATG_TGFb_CIS_dn", "ATG_VDRE_CIS_up", "ATG_VDRE_CIS_dn", "ATG_Xbp1_CIS_up", "ATG_Xbp1_CIS_dn", "ATG_AR_TRANS_up", "ATG_AR_TRANS_dn", "ATG_CAR_TRANS_up", "ATG_CAR_TRANS_dn", "ATG_ERa_TRANS_up", "ATG_ERa_TRANS_dn", "ATG_ERRa_TRANS_dn", "ATG_ERRg_TRANS_up", "ATG_ERRg_TRANS_dn", "ATG_FXR_TRANS_up", "ATG_FXR_TRANS_dn", "ATG_GR_TRANS_up", "ATG_GR_TRANS_dn", "ATG_HNF4a_TRANS_up", "ATG_HNF4a_TRANS_dn", "ATG_LXRa_TRANS_up", "ATG_LXRa_TRANS_dn", "ATG_LXRb_TRANS_up", "ATG_LXRb_TRANS_dn", "ATG_NURR1_TRANS_up", "ATG_NURR1_TRANS_dn", "ATG_PPARa_TRANS_up", "ATG_PPARa_TRANS_dn", "ATG_PPARd_TRANS_up", "ATG_PPARg_TRANS_up", "ATG_PXR_TRANS_up", "ATG_PXR_TRANS_dn", "ATG_RARa_TRANS_up", "ATG_RARa_TRANS_dn", "ATG_RARb_TRANS_up", "ATG_RARb_TRANS_dn", "ATG_RARg_TRANS_up", "ATG_RARg_TRANS_dn", "ATG_RORb_TRANS_dn", "ATG_RORg_TRANS_up", "ATG_RORg_TRANS_dn", "ATG_RXRa_TRANS_up", "ATG_RXRa_TRANS_dn", "ATG_RXRb_TRANS_up", "ATG_RXRb_TRANS_dn", "ATG_THRa1_TRANS_up", "ATG_THRa1_TRANS_dn", "ATG_VDR_TRANS_up", "ATG_VDR_TRANS_dn", "BSK_3C_Eselectin_down", "BSK_3C_Eselectin_up", "BSK_3C_HLADR_down", "BSK_3C_ICAM1_down", "BSK_3C_IL8_down", "BSK_3C_IL8_up", "BSK_3C_MCP1_down", "BSK_3C_MCP1_up", "BSK_3C_MIG_down", "BSK_3C_Proliferation_down", "BSK_3C_SRB_down", "BSK_3C_Thrombomodulin_down", "BSK_3C_Thrombomodulin_up", "BSK_3C_TissueFactor_down", "BSK_3C_TissueFactor_up", "BSK_3C_uPAR_down", "BSK_3C_uPAR_up", "BSK_3C_VCAM1_down", "BSK_4H_Eotaxin3_down", "BSK_4H_Eotaxin3_up", "BSK_4H_MCP1_down", "BSK_4H_Pselectin_down", "BSK_4H_Pselectin_up", "BSK_4H_SRB_down", "BSK_4H_uPAR_down", "BSK_4H_uPAR_up", "BSK_4H_VCAM1_down", "BSK_4H_VEGFRII_down", "BSK_4H_VEGFRII_up", "BSK_BE3C_HLADR_down", "BSK_BE3C_HLADR_up", "BSK_BE3C_IL1a_down", "BSK_BE3C_IL1a_up", "BSK_BE3C_IP10_down", "BSK_BE3C_MIG_down", "BSK_BE3C_MMP1_down", "BSK_BE3C_MMP1_up", "BSK_BE3C_PAI1_down", "BSK_BE3C_PAI1_up", "BSK_BE3C_SRB_down", "BSK_BE3C_tPA_down", "BSK_BE3C_tPA_up", "BSK_BE3C_uPA_down", "BSK_BE3C_uPA_up", "BSK_BE3C_uPAR_down", "BSK_BE3C_uPAR_up", "BSK_CASM3C_HLADR_down", "BSK_CASM3C_HLADR_up", "BSK_CASM3C_IL6_down", "BSK_CASM3C_IL6_up", "BSK_CASM3C_IL8_down", "BSK_CASM3C_IL8_up", "BSK_CASM3C_LDLR_down", "BSK_CASM3C_LDLR_up", "BSK_CASM3C_MCP1_down", "BSK_CASM3C_MCP1_up", "BSK_CASM3C_MCSF_down", "BSK_CASM3C_MCSF_up", "BSK_CASM3C_MIG_down", "BSK_CASM3C_MIG_up", "BSK_CASM3C_Proliferation_down", "BSK_CASM3C_Proliferation_up", "BSK_CASM3C_SAA_down", "BSK_CASM3C_SAA_up", "BSK_CASM3C_SRB_down", "BSK_CASM3C_Thrombomodulin_down", "BSK_CASM3C_Thrombomodulin_up", "BSK_CASM3C_TissueFactor_down", "BSK_CASM3C_TissueFactor_up", "BSK_CASM3C_uPAR_down", "BSK_CASM3C_uPAR_up", "BSK_CASM3C_VCAM1_down", "BSK_CASM3C_VCAM1_up", "BSK_hDFCGF_CollagenIII_down", "BSK_hDFCGF_CollagenIII_up", "BSK_hDFCGF_EGFR_down", "BSK_hDFCGF_EGFR_up", "BSK_hDFCGF_IL8_down", "BSK_hDFCGF_IP10_down", "BSK_hDFCGF_IP10_up", "BSK_hDFCGF_MCSF_down", "BSK_hDFCGF_MIG_down", "BSK_hDFCGF_MIG_up", "BSK_hDFCGF_MMP1_down", "BSK_hDFCGF_MMP1_up", "BSK_hDFCGF_PAI1_down", "BSK_hDFCGF_PAI1_up", "BSK_hDFCGF_Proliferation_down", "BSK_hDFCGF_Proliferation_up", "BSK_hDFCGF_SRB_down", "BSK_hDFCGF_SRB_up", "BSK_hDFCGF_TIMP1_down", "BSK_hDFCGF_TIMP1_up", "BSK_hDFCGF_VCAM1_down", "BSK_KF3CT_ICAM1_down", "BSK_KF3CT_ICAM1_up", "BSK_KF3CT_IL1a_down", "BSK_KF3CT_IL1a_up", "BSK_KF3CT_IP10_down", "BSK_KF3CT_IP10_up", "BSK_KF3CT_MCP1_down", "BSK_KF3CT_MCP1_up", "BSK_KF3CT_MMP9_down", "BSK_KF3CT_SRB_down", "BSK_KF3CT_TIMP2_down", "BSK_KF3CT_TIMP2_up", "BSK_KF3CT_uPA_down", "BSK_LPS_CD40_down", "BSK_LPS_Eselectin_down", "BSK_LPS_Eselectin_up", "BSK_LPS_IL1a_down", "BSK_LPS_IL1a_up", "BSK_LPS_IL8_down", "BSK_LPS_IL8_up", "BSK_LPS_MCP1_down", "BSK_LPS_MCP1_up", "BSK_LPS_MCSF_down", "BSK_LPS_PGE2_down", "BSK_LPS_PGE2_up", "BSK_LPS_SRB_down", "BSK_LPS_TissueFactor_down", "BSK_LPS_TissueFactor_up", "BSK_LPS_TNFa_down", "BSK_LPS_TNFa_up", "BSK_LPS_VCAM1_down", "BSK_SAg_CD38_down", "BSK_SAg_CD38_up", "BSK_SAg_CD40_down", "BSK_SAg_CD69_down", "BSK_SAg_Eselectin_down", "BSK_SAg_Eselectin_up", "BSK_SAg_IL8_down", "BSK_SAg_IL8_up", "BSK_SAg_MCP1_down", "BSK_SAg_MCP1_up", "BSK_SAg_MIG_down", "BSK_SAg_PBMCCytotoxicity_down", "BSK_SAg_PBMCCytotoxicity_up", "BSK_SAg_Proliferation_down", "BSK_SAg_SRB_down", "OT_AR_ARSRC1_0480", "OT_AR_ARSRC1_0960", "OT_ER_ERaERa_0480", "OT_ER_ERaERa_1440", "OT_ER_ERaERb_0480", "OT_ER_ERaERb_1440", "OT_ER_ERbERb_0480", "OT_ER_ERbERb_1440", "OT_ERa_EREGFP_0120", "OT_ERa_EREGFP_0480", "OT_FXR_FXRSRC1_0480", "OT_FXR_FXRSRC1_1440", "OT_NURR1_NURR1RXRa_0480", "OT_NURR1_NURR1RXRa_1440", "OT_PPARg_PPARgSRC1_0480", "OT_PPARg_PPARgSRC1_1440", "TOX21_AR_BLA_Agonist_ratio", "TOX21_AR_BLA_Antagonist_ratio", "TOX21_AR_BLA_Antagonist_viability", "TOX21_AR_LUC_MDAKB2_Agonist", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", "TOX21_Aromatase_Inhibition", "TOX21_Aromatase_Inhibition_viability", "TOX21_ELG1_LUC_Agonist", "TOX21_ELG1_LUC_Agonist_viability", "TOX21_ERa_BLA_Agonist_ratio", "TOX21_ERa_BLA_Antagonist_ratio", "TOX21_ERa_BLA_Antagonist_viability", "TOX21_ERa_LUC_VM7_Agonist", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", "TOX21_GR_BLA_Agonist_ratio", "TOX21_GR_BLA_Antagonist_ratio", "TOX21_GR_BLA_Antagonist_viability", "TOX21_MMP_ratio_down", "TOX21_MMP_ratio_up", "TOX21_PPARg_BLA_Agonist_ratio", "TOX21_TR_LUC_GH3_Antagonist", "TOX21_TR_LUC_GH3_Antagonist_viability", "TOX21_AhR_LUC_Agonist", "TOX21_AhR_LUC_Agonist_viability", "TOX21_ARE_BLA_agonist_ratio", "TOX21_HSE_BLA_agonist_ratio", "TOX21_p53_BLA_p1_ratio", "TOX21_FXR_BLA_agonist_ratio", "TOX21_FXR_BLA_antagonist_ratio", "TOX21_FXR_BLA_antagonist_viability", "TOX21_PPARd_BLA_agonist_ratio", "TOX21_PPARd_BLA_antagonist_ratio", "TOX21_PPARd_BLA_antagonist_viability", "TOX21_PPARg_BLA_antagonist_ratio", "TOX21_PPARg_BLA_antagonist_viability", "TOX21_VDR_BLA_agonist_ratio", "TOX21_VDR_BLA_antagonist_ratio", "TOX21_VDR_BLA_antagonist_viability", "TOX21_DT40", "TOX21_ARE_BLA_agonist_viability", "TOX21_HSE_BLA_agonist_viability", "TOX21_p53_BLA_p1_viability", "TOX21_FXR_BLA_agonist_viability", "TOX21_PPARd_BLA_Agonist_viability", "ATG_XTT_Cytotoxicity_up", "TOX21_p53_BLA_p2_ratio", "TOX21_p53_BLA_p2_viability", "TOX21_p53_BLA_p3_ratio", "TOX21_p53_BLA_p3_viability", "TOX21_p53_BLA_p4_ratio", "TOX21_p53_BLA_p4_viability", "TOX21_p53_BLA_p5_ratio", "TOX21_p53_BLA_p5_viability", "TOX21_VDR_BLA_Agonist_viability", "TOX21_ESRE_BLA_ratio", "TOX21_ESRE_BLA_viability", "TOX21_NFkB_BLA_agonist_ratio", "TOX21_NFkB_BLA_agonist_viability", "TOX21_RAR_LUC_Agonist", "TOX21_RAR_LUC_Agonist_viability", "TOX21_RORg_LUC_CHO_Antagonist", "TOX21_RORg_LUC_CHO_Antagonist_viability", "BSK_MyoF_SRB_down", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", "TOX21_RXR_BLA_Agonist_ratio", "TOX21_RXR_BLA_Agonist_viability", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", "TOX21_RAR_LUC_Antagonist", "TOX21_RAR_LUC_Antagonist_viability", "TOX21_H2AX_HTRF_CHO_Agonist_ratio", "TOX21_AP1_BLA_Agonist_ratio", "TOX21_AP1_BLA_Agonist_viability", "ACEA_AR_agonist_AUC_viability", "ACEA_ER_AUC_viability", "ACEA_AR_antagonist_AUC_viability", "TOX21_TSHR_HTRF_Agonist_ratio", "TOX21_TSHR_HTRF_Antagonist_ratio", "TOX21_TSHR_HTRF_wt_ratio", "TOX21_CAR_Agonist", "TOX21_CAR_Agonist_viabillity", "TOX21_CAR_Antagonist", "TOX21_CAR_Antagonist_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", "TOX21_ERR_Agonist", "TOX21_ERR_Antagonist", "TOX21_ERR_viability", "TOX21_H2AX_HTRF_CHO_viability", "TOX21_HDAC_Inhibition", "TOX21_HDAC_Inhibition_viability", "TOX21_HRE_BLA_Agonist_ratio", "TOX21_HRE_BLA_Agonist_viability", "TOX21_PGC_ERR_Agonist", "TOX21_PGC_ERR_Antagonist", "TOX21_PGC_ERR_viability", "TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEK293_FLO_16hr_viability", "TOX21_RT_HEK293_FLO_24hr_viability", "TOX21_RT_HEK293_FLO_32hr_viability", "TOX21_RT_HEK293_FLO_40hr_viability", "TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEK293_GLO_16hr_viability", "TOX21_RT_HEK293_GLO_24hr_viability", "TOX21_RT_HEK293_GLO_32hr_viability", "TOX21_RT_HEK293_GLO_40hr_viability", "TOX21_RT_HEPG2_FLO_08hr_viability", "TOX21_RT_HEPG2_FLO_16hr_ctrl_viability", "TOX21_RT_HEPG2_FLO_24hr_viability", "TOX21_RT_HEPG2_FLO_32hr_ctrl_viability", "TOX21_RT_HEPG2_FLO_40hr_ctrl_viability", "TOX21_RT_HEPG2_GLO_08hr_ctrl_viability", "TOX21_RT_HEPG2_GLO_16hr_ctrl_viability", "TOX21_RT_HEPG2_GLO_32hr_ctrl_viability", "TOX21_RT_HEPG2_GLO_40hr_viability", "TOX21_SHH_3T3_GLI3_Agonist", "TOX21_SHH_3T3_GLI3_Agonist_viability", "TOX21_SHH_3T3_GLI3_Antagonist", "TOX21_SHH_3T3_GLI3_Antagonist_viability", "TOX21_ERb_BLA_Antagonist_ratio", "TOX21_ERb_BLA_Antagonist_viability", "TOX21_ERb_BLA_Agonist_ratio", "TOX21_ERb_BLA_Agonist_viability", "TOX21_PR_BLA_Agonist_ratio", "TOX21_PR_BLA_Agonist_viability", "TOX21_PR_BLA_Antagonist_ratio", "TOX21_PR_BLA_Antagonist_viability", "TOX21_DT40_100", "TOX21_DT40_657", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", "TOX21_RT_HEPG2_GLO_24hr_ctrl_viability", "TOX21_PXR_viability", "TOX21_PXR_Agonist", "TOX21_TRHR_HEK293_Agonist", "TOX21_TRHR_HEK293_Antagonist", "TOX21_CASP3_HEPG2", "TOX21_CASP3_HEPG2_viability", "TOX21_CASP3_CHO", "TOX21_CASP3_CHO_viability", "TOX21_SBE_BLA_Antagonist_ratio", "TOX21_SBE_BLA_Antagonist_viability", "TOX21_SBE_BLA_Agonist_ratio", "TOX21_SBE_BLA_Agonist_viability", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist", "CCTE_Harrill_HTTr_Viability_MCF7_DMEM_6hr", "CCTE_Harrill_HTTr_Apoptosis_MCF7_DMEM_6hr", "BSK_BF4T_SRB_down", "BSK_IMphg_SRB_down", "BSK_IMphg_SRB.Mphg_down"], "assay_component_endpoint_desc": ["Data from the assay component ACEA_ER_80hr was analyzed into 2 assay endpoints. \nThis assay endpoint, ACEA_ER_80hr_Positive, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene ESR1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"steroidal\".", "Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. \nThis assay endpoint, APR_HepG2_CellLoss_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. \nThis assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component ATG_Ahr_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_Ahr_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AHR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", "ATG_Ahr_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "ATG_AP_1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_AP_2_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_AP_2_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TFAP2A and TFAP2B and TFAP2D. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-turn-helix leucine zipper.", "ATG_AP_2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_BRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.", "ATG_BRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_C_EBP_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_C_EBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CEBPB. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "ATG_C_EBP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_CRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "ATG_CRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_DR4_LXR_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_DR4_LXR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2 and NR1H3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_DR5_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_E_Box_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_E_Box_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene USF1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", "ATG_E_Box_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_E2F_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_E2F_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene E2F1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is E2F transcription factor.", "ATG_E2F_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", "Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "ATG_ERE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_Ets_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_Ets_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ETS1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is winged helix-turn-helix.", "ATG_Ets_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_FoxA2_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_FoxA2_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXA2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", "ATG_FoxA2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_FoxO_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_FoxO_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXO1 and FOXO3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", "ATG_FoxO_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_GATA_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_GATA_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GATA1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is GATA proteins.", "ATG_GATA_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "ATG_GLI_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_GRE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_GRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "ATG_GRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_HIF1a_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", "ATG_HIF1a_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_HNF6_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_HNF6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ONECUT1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is homeobox protein.", "ATG_HNF6_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_HSE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.", "ATG_HSE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_IR1_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_IR1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_IR1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_ISRE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_ISRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene IRF1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is interferon regulatory factors.", "ATG_ISRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", "Data from the assay component ATG_Myb_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_Myb_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYB. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is MYB proteins.", "ATG_Myb_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_Myc_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_Myc_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYC. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.", "ATG_Myc_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_NF_kB_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_NF_kB_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFKB1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is NF-kappa B.", "ATG_NF_kB_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_NFI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear factor I.", "ATG_NFI_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_NRF1_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_NRF1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NRF1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear respiratory factors.", "ATG_NRF1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "ATG_NRF2_ARE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.", "ATG_Oct_MLP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_p53_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_p53_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TP53. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", "ATG_p53_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_Pax6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is paired box protein.", "Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_PBREM_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_PBREM_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_PPRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_PPRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_PXRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "ATG_RORE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_Sox_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_Sox_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SOX1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.", "ATG_Sox_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", "ATG_Sp1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_SREBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.", "ATG_SREBP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_STAT3_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_STAT3_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene STAT3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is stat protein.", "ATG_STAT3_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_TGFb_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_TGFb_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TGFB1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", "ATG_TGFb_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_VDRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "ATG_Xbp1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_AR_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_AR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "ATG_AR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_CAR_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_CAR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_CAR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "ATG_ERa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "ATG_ERRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_ERRg_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_ERRg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "ATG_ERRg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_FXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_FXR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_GR_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_GR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "ATG_GR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_HNF4a_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_HNF4a_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HNF4A. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "ATG_HNF4a_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_LXRa_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_LXRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H3. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_LXRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_LXRb_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_LXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_LXRb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_NURR1_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_NURR1_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "ATG_NURR1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_PPARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_PPARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_PPARd_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_PPARd_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARD. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_PXR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_RARa_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_RARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_RARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_RARb_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_RARb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARB. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_RARb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_RARg_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_RARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_RARg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "ATG_RORb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_RORg_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_RORg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORC. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "ATG_RORg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_RXRa_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_RXRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_RXRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_RXRb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_THRa1_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_THRa1_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene THRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_THRa1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component ATG_VDR_TRANS was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ATG_VDR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "ATG_VDR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.", "Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"selectins\".", "Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"selectins\".", "Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"MHC Class II\".", "Data from the assay component BSK_3C_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"Immunoglobulin CAM\".", "Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Thrombomodulin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"gpcr\" intended target family, where the subfamily is \"rhodopsin-like receptor\".", "Data from the assay component BSK_3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"gpcr\" intended target family, where the subfamily is \"rhodopsin-like receptor\".", "Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"coagulation factor\".", "Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"coagulation factor\".", "Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator\".", "Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator\".", "Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"Immunoglobulin CAM\".", "Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"selectins\".", "Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"selectins\".", "Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_4H_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator\".", "Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator\".", "Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"Immunoglobulin CAM\".", "Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"kinase\" intended target family, where the subfamily is \"receptor tyrosine kinase\".", "Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"kinase\" intended target family, where the subfamily is \"receptor tyrosine kinase\".", "Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"MHC Class II\".", "Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"MHC Class II\".", "Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_BE3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease\" intended target family, where the subfamily is \"matrix metalloproteinase\".", "Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease\" intended target family, where the subfamily is \"matrix metalloproteinase\".", "Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator inhibitor\".", "Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator inhibitor\".", "Data from the assay component BSK_BE3C_SRB was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_BE3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease\" intended target family, where the subfamily is \"serine protease\".", "Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease\" intended target family, where the subfamily is \"serine protease\".", "Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease\" intended target family, where the subfamily is \"serine protease\".", "Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease\" intended target family, where the subfamily is \"serine protease\".", "Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator\".", "Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator\".", "Data from the assay component BSK_CASM3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"MHC Class II\".", "Data from the assay component BSK_CASM3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_HLADR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"MHC Class II\".", "Data from the assay component BSK_CASM3C_IL6 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL6_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_CASM3C_IL6 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL6_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_CASM3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_CASM3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"misc protein\" intended target family, where the subfamily is \"LDL receptor\".", "Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"misc protein\" intended target family, where the subfamily is \"LDL receptor\".", "Data from the assay component BSK_CASM3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_CASM3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"colony stimulating factor\".", "Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"colony stimulating factor\".", "Data from the assay component BSK_CASM3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_CASM3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_CASM3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_CASM3C_Proliferation_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"proliferation\".", "Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"apolipoproteins\".", "Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"apolipoproteins\".", "Data from the assay component BSK_CASM3C_SRB was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_CASM3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"gpcr\" intended target family, where the subfamily is \"rhodopsin-like receptor\".", "Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"gpcr\" intended target family, where the subfamily is \"rhodopsin-like receptor\".", "Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"coagulation factor\".", "Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"coagulation factor\".", "Data from the assay component BSK_CASM3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator\".", "Data from the assay component BSK_CASM3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator\".", "Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"Immunoglobulin CAM\".", "Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"Immunoglobulin CAM\".", "Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"collagen\".", "Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"collagen\".", "Data from the assay component BSK_hDFCGF_EGFR was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_EGFR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"kinase\" intended target family, where the subfamily is \"receptor tyrosine kinase\".", "Data from the assay component BSK_hDFCGF_EGFR was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_EGFR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"kinase\" intended target family, where the subfamily is \"receptor tyrosine kinase\".", "Data from the assay component BSK_hDFCGF_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"colony stimulating factor\".", "Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease\" intended target family, where the subfamily is \"matrix metalloproteinase\".", "Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease\" intended target family, where the subfamily is \"matrix metalloproteinase\".", "Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator inhibitor\".", "Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"plasmogen activator inhibitor\".", "Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_hDFCGF_Proliferation_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"proliferation\".", "Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_hDFCGF_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell morphology\" intended target family, where the subfamily is \"cell conformation\".", "Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease inhibitor\" intended target family, where the subfamily is \"metalloproteinase inhibitor\".", "Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease inhibitor\" intended target family, where the subfamily is \"metalloproteinase inhibitor\".", "Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"Immunoglobulin CAM\".", "Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"Immunoglobulin CAM\".", "Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"Immunoglobulin CAM\".", "Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease\" intended target family, where the subfamily is \"matrix metalloproteinase\".", "Data from the assay component BSK_KF3CT_SRB was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_KF3CT_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease inhibitor\" intended target family, where the subfamily is \"metalloproteinase inhibitor\".", "Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease inhibitor\" intended target family, where the subfamily is \"metalloproteinase inhibitor\".", "Data from the assay component BSK_KF3CT_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"protease\" intended target family, where the subfamily is \"serine protease\".", "Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"inflammatory factor\".", "Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"selectins\".", "Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"selectins\".", "Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"colony stimulating factor\".", "Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"gpcr\" intended target family, where the subfamily is \"rhodopsin-like receptor\".", "Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"gpcr\" intended target family, where the subfamily is \"rhodopsin-like receptor\".", "Data from the assay component BSK_LPS_SRB was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_LPS_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"coagulation factor\".", "Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"coagulation factor\".", "Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"inflammatory factor\".", "Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"inflammatory factor\".", "Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"Immunoglobulin CAM\".", "Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"other cytokine\".", "Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"other cytokine\".", "Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"inflammatory factor\".", "Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"inflammatory factor\".", "Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"selectins\".", "Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell adhesion molecules\" intended target family, where the subfamily is \"selectins\".", "Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"interleukins\".", "Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_SAg_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cytokine\" intended target family, where the subfamily is \"chemotactic factor\".", "Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"proliferation\".", "Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain-of-signal activity can be used to understand changes in the viability. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. \nThis assay endpoint, BSK_SAg_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"steroidal\".", "Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"steroidal\".", "Data from the assay component OT_ER_ERaERa_0480 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_ER_ERaERa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"steroidal\".", "Data from the assay component OT_ER_ERaERa_1440 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_ER_ERaERa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"steroidal\".", "Data from the assay component OT_ER_ERaERb_0480 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_ER_ERaERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"steroidal\".", "Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"steroidal\".", "Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"steroidal\".", "Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"steroidal\".", "Data from the assay component OT_ERa_GFPERaERE_0120 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_ERa_EREGFP_0120, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"steroidal\".", "Data from the assay component OT_ERa_GFPERaERE_0480 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_ERa_EREGFP_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"steroidal\".", "Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"non-steroidal\".", "Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"non-steroidal\".", "Data from the assay component OT_NURR1_NURR1RXRa_0480 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_NURR1_NURR1RXRa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"non-steroidal\".", "Data from the assay component OT_NURR1_NURR1RXRa_1440 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_NURR1_NURR1RXRa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"non-steroidal\".", "Data from the assay component OT_PPARg_PPARgSRC1_0480 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_PPARg_PPARgSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"non-steroidal\".", "Data from the assay component OT_PPARg_PPARgSRC1_1440 was analyzed into 1 assay endpoint. \nThis assay endpoint, OT_PPARg_PPARgSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"nuclear receptor\" intended target family, where the subfamily is \"non-steroidal\".", "Data from the assay component TOX21_AR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", "TOX21_Aromatase_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ELG1_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ELG1_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATAD5.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is atpase.", "TOX21_ELG1_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ERa_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component TOX21_ERa_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_ERa_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_GR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component TOX21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand gene activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_GR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", "Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. The assay endpoin, TOX21_MMP_ratio_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", "Data from the assay component TOX21_PPARg_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_AhR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AhR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AHR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic helix-loop-helix protein.", "TOX21_AhR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ", "Data from the assay component TOX21_HSE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_HSE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is heat shock protein.", "Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", "Data from the assay component TOX21_FXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "TOX21_FXR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_PPARd_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component TOX21_PPARd_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "TOX21_PPARd_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_PPARg_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "TOX21_PPARg_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_VDR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component TOX21_VDR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "TOX21_VDR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.", "TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_HSE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_p53_BLA_p1_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_FXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_PPARd_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ATG_XTT_Cytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, ATG_XTT_Cytotoxicity_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_p53_BLA_p2_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", "TOX21_p53_BLA_p2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_p53_BLA_p3_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_p53_BLA_p3_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter,  gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", "TOX21_p53_BLA_p3_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_p53_BLA_p4_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", "TOX21_p53_BLA_p4_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_p53_BLA_p5_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", "TOX21_p53_BLA_p5_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ESRE_BLA_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ATF6.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.", "TOX21_ESRE_BLA_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_NFkB_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_NFkB_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is NF-kappa B.", "TOX21_NFkB_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_RAR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "TOX21_RAR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component BSK_MyoF_SRB was analyzed at the endpoint, BSK_MyoF_SRB_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.", "Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_RXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where subfamily is NF-kappa B.", "TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_RAR_LUC_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.", "TOX21_RAR_LUC_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is histone.", "Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "TOX21_AP1_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle target family, where the subfamily is cytotoxicity.", "Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component ACEA_ER_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. \nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the \"cell cycle\" intended target family, where the subfamily is \"cytotoxicity\".", "Data from the assay component TOX21_TSHR_HTRF_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", "Data from the assay component TOX21_TSHR_HTRF_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this one serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", "Data from the assay component TOX21_TSHR_HTRF_wt_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_wt_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", "Data from the assay component TOX21_CAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "TOX21_CAR_Agonist_viabillity used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_CAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "TOX21_CAR_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_H2AX_HTRF_CHO_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_HDAC_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HDAC_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HDAC1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", "TOX21_HDAC_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_HRE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is hypoxia-response element.", "TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_PGC_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEPG2_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEPG2_FLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEPG2_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEPG2_GLO_08hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEPG2_GLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEPG2_GLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEPG2_GLO_40hr_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_SHH_3T3_GLI3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", "TOX21_SHH_3T3_GLI3_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_SHH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", "TOX21_SHH_3T3_GLI3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_ERb_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ERb_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_PR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_PR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_PR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.", "Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_RT_HEPG2_GLO_24hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "The assay component endpoint  TOX21_PXR_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.", "TOX21_TRHR_HEK293_Agonist  used a type of biochemical reporter where gain-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", "TOX21_TRHR_HEK293_Antagonist  used a type of biochemical reporter where loss-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", "The assay component endpoint  TOX21_CASP3_HEPG2 was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_HEPG2 assay is a homogeneous, luminescent assay that measures caspase-3 activity following compound treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.", "The assay component endpoint  TOX21_CASP3_HEPG2_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", "The assay component endpoint  TOX21_CASP3_CHO was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_CHO assay is a homogeneous, luminescent assay that measures caspase-3 activity following chemical treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.", "The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_SBE_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.", "The assay component endpoint  TOX21_SBE_BLA_Antagonist_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_SBE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.", "The assay component endpoint  TOX21_SBE_BLA_Agonist_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. \r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist was analyzed into 1 assay endpoint. \r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist, was analyzed in the positive fitting direction relative to DMSO as the baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist was analyzed into 1 assay endpoint. \r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist was analyzed into 1 assay endpoint. \r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist, was analyzed in the positive fitting direction relative to DMSO as the baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", "The assay component endpoint CCTE_Harrill_HTTr_Viability_MCF7_DMEM_6hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion to understand changes in cytotoxicity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", "The assay component endpoint CCTE_Harrill_HTTr_Apoptosis_MCF7_DMEM_6hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate activation of caspase-3/7 using the CellEvent Caspase 3/7 Green detection reagent to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is apoptosis.", "Data from the assay component BSK_BF4T_SRB  was analyzed at the endpoint, BSK_BF4T_SRB_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.", "Data from the assay component BSK_IMphg_SRB  was analyzed at the endpoint, BSK_IMphg_SRB_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.", "Data from the assay component BSK_IMphg_SRB.Mphg  was analyzed at the endpoint, BSK_IMphg_SRB.Mphg_down, in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of  viability reporter, loss-of-signal activity can be used to understand cellular changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'."], "assay_function_type": ["signaling", "viability", "reporter gene", "binding", "ratio", "agonist", "antagonist", "inducer"], "normalized_data_type": ["percent_activity", "log2_fold_induction", "log10_fold_induction"], "analysis_direction": ["positive", "negative"], "burst_assay": [0, 1], "key_positive_control": ["17b-Estradiol", "Camptothecin;Anisomycin;Paclitaxel;CCCP", "6-formylindolo carbazole", "NA", "Forskolin", "9-cis-Retinoic acid", "4-hydroxytamoxifen", "Dexamethasone", "Geldanamycin", "Rosiglitazone", "Rifampicin", "6a-Fluorotestosterone", "CDCA", "T0901317", "GW0742", "GW7647", "Retinoic Acid", "T3", "1a,25-Dihydroxyvitamin D3", "colchicine", "4,5-alpha-Dihydrotestosterone", "(Z)-4-Hydroxytamoxifen", "GW4064", "Isoproterenol;Fenoterol", "GW1929", "R1881", "Cyproterone acetate", "tetraoctylammonium bromide", "Nilutamide", "Letrozole", "5-Fluorouridine", "Mifeprostone", "FCCP", "1 nM T3", "Omeprazole", "Beta-Naphthoflavone", "17-AAG", "Mitomycin C;Nutlin3", "Chenodeoxycholic acid", "Guggulsterone", "L-165,041", "MK886", "GW9662", "Calcitriol", "1alpha,25-Dihydroxy vitamin D3", "Tetraoctyl ammonium bromide", "TNFa", "Retinol", "TO-901317", "ER50891", "Etoposide", "EGF", "MG 132", "TSH", "no TSH stimulation", "CITCO", "PK11195", "Genistein", "XCT790", "Trichostatin A", "Cobalt(II)chloride hexahydrate", "SAG", "Cyclopamine", "promegestone (R5020)", "RU486", "46 uM rifampicin ", "TRH", "1 nM T293", "Staurosporine", "TGFb", "DMSO", "dihydroxytestosterone (DHT)", "1 nM N6"], "signal_direction": ["gain", "loss"], "intended_target_type": ["pathway", "cellular", "protein", "cell"], "intended_target_type_sub": ["pathway-specified", "cellular", "transcription factor", "protein-specified", "receptor", "protein-unspecified", "enzyme", "mitochondria"], "intended_target_family": ["nuclear receptor", "cell cycle", "dna binding", "growth factor", "cell adhesion molecules", "cytokine", "gpcr", "kinase", "protease", "misc protein", "cell morphology", "protease inhibitor", "cyp", "hydrolase", "apoptosis", "growth factor receptor"], "intended_target_family_sub": ["steroidal", "cytotoxicity", "basic helix-loop-helix protein", "basic leucine zipper", "basic helix-turn-helix leucine zipper", "Smad protein", "non-steroidal", "E2F transcription factor", "zinc finger", "winged helix-turn-helix", "forkhead box protein", "GATA proteins", "homeobox protein", "heat shock protein", "interferon regulatory factors", "MYB proteins", "basic helix-loop-helix leucine zipper", "NF-kappa B", "nuclear factor I", "nuclear respiratory factors", "POU domain protein", "tumor suppressor", "paired box protein", "orphan", "HMG box protein", "stat protein", "transforming growth factor beta", "selectins", "MHC Class II", "Immunoglobulin CAM", "interleukins", "chemotactic factor", "rhodopsin-like receptor", "coagulation factor", "plasmogen activator", "receptor tyrosine kinase", "matrix metalloproteinase", "plasmogen activator inhibitor", "serine protease", "LDL receptor", "colony stimulating factor", "proliferation", "apolipoproteins", "collagen", "cell conformation", "metalloproteinase inhibitor", "inflammatory factor", "other cytokine", "steroidogenesis-related", "atpase", "organelle conformation", "DNA repair", "histone H2A", "thyrotropin-releasing hormone receptor", "xenobiotic", "NA", "hypoxia-response element", "caspase", "apoptosis"], "fit_all": [0], "new_AssayEndpointName": ["ACEA_ER_80hr", null, "OT_AR_ARSRC1_0480", "OT_AR_ARSRC1_0960", "OT_ER_ERaERa_0480", "OT_ER_ERaERa_1440", "OT_ER_ERaERb_0480", "OT_ER_ERaERb_1440", "OT_ER_ERbERb_0480", "OT_ER_ERbERb_1440", "OT_FXR_FXRSRC1_0480", "OT_FXR_FXRSRC1_1440", "OT_NURR1_NURR1RXRa_0480", "OT_NURR1_NURR1RXRa_1440", "OT_PPARg_PPARgSRC1_0480", "OT_PPARg_PPARgSRC1_1440", "TOX21_AR_BLA_Agonist_ratio", "TOX21_AR_BLA_Antagonist_ratio", "TOX21_AR_BLA_Antagonist_viability", "TOX21_AR_LUC_MDAKB2_Agonist", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", "TOX21_Aromatase_Inhibition", "TOX21_Aromatase_Inhibition_viability", "TOX21_ELG1_LUC_Agonist", "TOX21_ELG1_LUC_Agonist_viability", "TOX21_ERa_BLA_Agonist_ratio", "TOX21_ERa_BLA_Antagonist_ratio", "TOX21_ERa_BLA_Antagonist_viability", "TOX21_ERa_LUC_VM7_Agonist", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", "TOX21_GR_BLA_Agonist_ratio", "TOX21_GR_BLA_Antagonist_ratio", "TOX21_GR_BLA_Antagonist_viability", "TOX21_PPARg_BLA_Agonist_ratio", "TOX21_TR_LUC_GH3_Antagonist", "TOX21_TR_LUC_GH3_Antagonist_viability", "TOX21_AhR_LUC_Agonist", "TOX21_AhR_LUC_Agonist_viability", "TOX21_p53_BLA_p1_ratio", "TOX21_DT40", "TOX21_ARE_BLA_agonist_viability", "TOX21_HSE_BLA_agonist_viability", "TOX21_p53_BLA_p1_viability", "TOX21_FXR_BLA_agonist_viability", "TOX21_PPARd_BLA_Agonist_viability", "TOX21_p53_BLA_p2_ratio", "TOX21_p53_BLA_p2_viability", "TOX21_p53_BLA_p3_ratio", "TOX21_p53_BLA_p3_viability", "TOX21_p53_BLA_p4_ratio", "TOX21_p53_BLA_p4_viability", "TOX21_p53_BLA_p5_ratio", "TOX21_p53_BLA_p5_viability", "TOX21_VDR_BLA_Agonist_viability", "TOX21_ESRE_BLA_ratio", "TOX21_ESRE_BLA_viability", "TOX21_NFkB_BLA_agonist_ratio", "TOX21_NFkB_BLA_agonist_viability", "TOX21_RAR_LUC_Agonist", "TOX21_RAR_LUC_Agonist_viability", "TOX21_RORg_LUC_CHO_Antagonist", "TOX21_RORg_LUC_CHO_Antagonist_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", "TOX21_RXR_BLA_Agonist_ratio", "TOX21_RXR_BLA_Agonist_viability", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", "TOX21_RAR_LUC_Antagonist", "TOX21_RAR_LUC_Antagonist_viability", "TOX21_H2AX_HTRF_CHO_Agonist_ratio", "TOX21_AP1_BLA_Agonist_ratio", "TOX21_AP1_BLA_Agonist_viability", "ACEA_AR_agonist_AUC_viability", "ACEA_ER_AUC_viability", "ACEA_AR_antagonist_AUC_viability", "TOX21_TSHR_HTRF_Agonist_ratio", "TOX21_TSHR_HTRF_Antagonist_ratio", "TOX21_CAR_Agonist", "TOX21_CAR_Antagonist", "TOX21_CAR_Antagonist_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", "TOX21_ERR_Agonist", "TOX21_ERR_Antagonist", "TOX21_ERR_viability", "TOX21_H2AX_HTRF_CHO_viability", "TOX21_HDAC_Inhibition", "TOX21_HDAC_Inhibition_viability", "TOX21_HRE_BLA_Agonist_ratio", "TOX21_HRE_BLA_Agonist_viability", "TOX21_PGC_ERR_Agonist", "TOX21_PGC_ERR_Antagonist", "TOX21_PGC_ERR_viability", "TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEK293_FLO_16hr_viability", "TOX21_RT_HEK293_FLO_24hr_viability", "TOX21_RT_HEK293_FLO_32hr_viability", "TOX21_RT_HEK293_FLO_40hr_viability", "TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEK293_GLO_16hr_viability", "TOX21_RT_HEK293_GLO_24hr_viability", "TOX21_RT_HEK293_GLO_32hr_viability", "TOX21_RT_HEK293_GLO_40hr_viability", "TOX21_RT_HEPG2_FLO_08hr_viability", "TOX21_RT_HEPG2_FLO_24hr_viability", "TOX21_RT_HEPG2_GLO_40hr_viability", "TOX21_SHH_3T3_GLI3_Agonist", "TOX21_SHH_3T3_GLI3_Agonist_viability", "TOX21_SHH_3T3_GLI3_Antagonist", "TOX21_SHH_3T3_GLI3_Antagonist_viability", "TOX21_ERb_BLA_Antagonist_ratio", "TOX21_ERb_BLA_Antagonist_viability", "TOX21_ERb_BLA_Agonist_ratio", "TOX21_ERb_BLA_Agonist_viability", "TOX21_PR_BLA_Agonist_ratio", "TOX21_PR_BLA_Agonist_viability", "TOX21_PR_BLA_Antagonist_ratio", "TOX21_PR_BLA_Antagonist_viability", "TOX21_DT40_100", "TOX21_DT40_657", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", "TOX21_PXR_viability", "TOX21_CASP3_HEPG2", "TOX21_CASP3_HEPG2_viability", "TOX21_CASP3_CHO", "TOX21_CASP3_CHO_viability", "TOX21_SBE_BLA_Antagonist_ratio", "TOX21_SBE_BLA_Antagonist_viability", "TOX21_SBE_BLA_Agonist_ratio", "TOX21_SBE_BLA_Agonist_viability", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist"], "old_AssayEndpointName": ["ACEA_ER_80hr", null, "OT_AR_ARSRC1_0480", "OT_AR_ARSRC1_0960", "OT_ER_ERaERa_0480", "OT_ER_ERaERa_1440", "OT_ER_ERaERb_0480", "OT_ER_ERaERb_1440", "OT_ER_ERbERb_0480", "OT_ER_ERbERb_1440", "OT_FXR_FXRSRC1_0480", "OT_FXR_FXRSRC1_1440", "OT_NURR1_NURR1RXRa_0480", "OT_NURR1_NURR1RXRa_1440", "OT_PPARg_PPARgSRC1_0480", "OT_PPARg_PPARgSRC1_1440", "TOX21_AR_BLA_Agonist_ratio", "TOX21_AR_BLA_Antagonist_ratio", "TOX21_AR_BLA_Antagonist_viability", "TOX21_AR_LUC_MDAKB2_Agonist", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", "TOX21_Aromatase_Inhibition", "TOX21_Aromatase_Inhibition_viability", "TOX21_ELG1_LUC_Agonist", "TOX21_ELG1_LUC_Agonist_viability", "TOX21_ERa_BLA_Agonist_ratio", "TOX21_ERa_BLA_Antagonist_ratio", "TOX21_ERa_BLA_Antagonist_viability", "TOX21_ERa_LUC_VM7_Agonist", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", "TOX21_GR_BLA_Agonist_ratio", "TOX21_GR_BLA_Antagonist_ratio", "TOX21_GR_BLA_Antagonist_viability", "TOX21_PPARg_BLA_Agonist_ratio", "TOX21_TR_LUC_GH3_Antagonist", "TOX21_TR_LUC_GH3_Antagonist_viability", "TOX21_AhR_LUC_Agonist", "TOX21_AhR_LUC_Agonist_viability", "TOX21_p53_BLA_p1_ratio", "TOX21_DT40", "TOX21_ARE_BLA_agonist_viability", "TOX21_HSE_BLA_agonist_viability", "TOX21_p53_BLA_p1_viability", "TOX21_FXR_BLA_agonist_viability", "TOX21_PPARd_BLA_Agonist_viability", "TOX21_p53_BLA_p2_ratio", "TOX21_p53_BLA_p2_viability", "TOX21_p53_BLA_p3_ratio", "TOX21_p53_BLA_p3_viability", "TOX21_p53_BLA_p4_ratio", "TOX21_p53_BLA_p4_viability", "TOX21_p53_BLA_p5_ratio", "TOX21_p53_BLA_p5_viability", "TOX21_VDR_BLA_Agonist_viability", "TOX21_ESRE_BLA_ratio", "TOX21_ESRE_BLA_viability", "TOX21_NFkB_BLA_agonist_ratio", "TOX21_NFkB_BLA_agonist_viability", "TOX21_RAR_LUC_Agonist", "TOX21_RAR_LUC_Agonist_viability", "TOX21_RORg_LUC_CHO_Antagonist", "TOX21_RORg_LUC_CHO_Antagonist_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", "TOX21_RXR_BLA_Agonist_ratio", "TOX21_RXR_BLA_Agonist_viability", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", "TOX21_RAR_LUC_Antagonist", "TOX21_RAR_LUC_Antagonist_viability", "TOX21_H2AX_HTRF_CHO_Agonist_ratio", "TOX21_AP1_BLA_Agonist_ratio", "TOX21_AP1_BLA_Agonist_viability", "ACEA_AR_agonist_AUC_viability", "ACEA_ER_AUC_viability", "ACEA_AR_antagonist_AUC_viability", "TOX21_TSHR_Agonist_ratio", "TOX21_TSHR_Antagonist_ratio", "TOX21_CAR_Agonist", "TOX21_CAR_Antagonist", "TOX21_CAR_Antagonist_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", "TOX21_ERR_Agonist", "TOX21_ERR_Antagonist", "TOX21_ERR_viability", "TOX21_H2AX_HTRF_CHO_viability", "TOX21_HDAC_Inhibition", "TOX21_HDAC_Inhibition_viability", "TOX21_HRE_BLA_Agonist_ratio", "TOX21_HRE_BLA_Agonist_viability", "TOX21_PGC_ERR_Agonist", "TOX21_PGC_ERR_Antagonist", "TOX21_PGC_ERR_viability", "TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEK293_FLO_16hr_viability", "TOX21_RT_HEK293_FLO_24hr_viability", "TOX21_RT_HEK293_FLO_32hr_viability", "TOX21_RT_HEK293_FLO_40hr_viability", "TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEK293_GLO_16hr_viability", "TOX21_RT_HEK293_GLO_24hr_viability", "TOX21_RT_HEK293_GLO_32hr_viability", "TOX21_RT_HEK293_GLO_40hr_viability", "TOX21_RT_HEPG2_FLO_08hr_viability", "TOX21_RT_HEPG2_FLO_24hr_viability", "TOX21_RT_HEPG2_GLO_40hr_viability", "TOX21_SSH_3T3_GLI3_Agonist", "TOX21_SSH_3T3_GLI3_Agonist_viability", "TOX21_SSH_3T3_GLI3_Antagonist", "TOX21_SSH_3T3_GLI3_Antagonist_viability", "TOX21_ERb_BLA_Antagonist_ratio", "TOX21_ERb_BLA_Antagonist_viability", "TOX21_ERb_BLA_Agonist_ratio", "TOX21_ERb_BLA_Agonist_viability", "TOX21_PR_BLA_Agonist_ratio", "TOX21_PR_BLA_Agonist_viability", "TOX21_PR_BLA_Antagonist_ratio", "TOX21_PR_BLA_Antagonist_viability", "TOX21_DT40_100", "TOX21_DT40_657", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", "TOX21_PXR_viability", "TOX21_CASP3_HEPG2", "TOX21_CASP3_HEPG2_viability", "TOX21_CASP3_CHO", "TOX21_CASP3_CHO_viability", "TOX21_SBE_BLA_Antagonist_ratio", "TOX21_SBE_BLA_Antagonist_viability", "TOX21_SBE_BLA_Agonist_ratio", "TOX21_SBE_BLA_Agonist_viability", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist"], "Assay_MOA": ["mayInformOn", null], "ModeofAction": ["DART - Estrogen Receptor Modulation", "Estrogen - Estrogen Receptor Modulation", "DART - Gene Expression", null, "Cancer - KCC8: Receptor Mediated Effects", "CardioTox - Endothelial Injury/Coagulation", null, "DART - Androgen Receptor Modulation", "Androgen - Androgen Receptor Modulation", "DART - Retinoid X Receptor Modulation", "Cancer - KCC10: Cell Proliferation/Death/Energetics", "AcuteTox - Cytotoxicity", "DART - Steroid Hormone Metabolism", "CardioTox - Cardiomyocyte/Myocardial Injury", "Other Steroid Hormone - Steroid Hormone Metabolism", "Cancer - KCC2: Genotoxic Effects", "CardioTox - Change in Vasoactivity", "Other Steroid Hormone - Glucocorticoid Receptor Modulation", "Thyroid Hormone - Thyroid Receptor Modulation", "DART - Aryl Hydrocarbon Receptor Modulation", "AcuteTox - p53 Signaling Pathway", "DART - p53 Signaling Pathway", "Cancer - KCC5: Oxidative Stress", "Cancer - KCC3: Alteration of DNA Repair/Genomic Stability", "AcuteTox - Oxidative Stress", "DART - Oxidative Stress", "Cancer - KCC6: Chronic Inflammation", "DART - Retinoic Acid Receptor Modulation", "Thyroid Hormone - TSH Receptor Modulation", "Thyroid Hormone - Thyroid Hormone Metabolic Process", "DART - Thyroid Hormone Metabolic Process", "DART - Estrogen-related Receptor Modulation", "Estrogen - Estrogen-related Receptor Modulation", "Cancer - KCC4: Epigenetic Alterations", "DART - Other Developmental Signaling Transcription Factors", "DART - Progesterone Receptor Modulation", "Other Steroid Hormone - Progesterone Receptor Modulation"], "MOA_ToxicityEndpoint": ["mayContributeTo", null], "ToxicityEndpoint": ["DART", "Estrogen", "cHTS", "Cancer", "CardioTox", null, "Androgen", "Acute Lethality", "Other Steroid Hormone", "Thyroid Hormone"], "Assay_MechanisticTarget": ["throughMechanisticTarget", null], "MechanisticTarget": ["Estrogen Receptor Modulation", "CardioTox_ER Alpha", null, "Androgen Receptor Modulation", "Farnesoid X-activated Receptor Modulation", "Retinoid X Receptor Modulation", "CardioTox_PPARG", "Peroxisome Proliferator Activated Receptor Modulation", "Cell Viability", "Aromatase Activity Modulation", "CardioTox_AroPro", "DNA Damage", "Glucocorticoid Receptor Modulation", "CardioTox_NR3C1", "Thyroid Receptor Modulation", "Aryl Hydrocarbon Receptor Modulation", "CardioTox_AHR", "p53 Modulation", "CardioTox_TP53", "DNA Repair", "Other Transcription Factors", "Oxidative Stress", "Inflammation", "CardioTox_NFKB", "Retinoic Acid Receptor Modulation", "RAR-related Orphan Receptor Modulation", "Histone Modification", "Cell Cycle", "CardioTox_AP-1", "TSH Receptor Modulation", "Constitutive Androstane\u00a0Receptor Modulation", "Estrogen-related Receptor Modulation", "CardioTox_H1FA", "Other Developmental Signaling Transcription Factors", "Progesterone Receptor Modulation", "Apoptosis"], "MT_NCIm_term": ["Gene Expression Regulation, Steroid Hormone Nuclear Receptor", "Estrogen Metabolic Process", null, null, "Androgen Metabolic Process", "Gene Expression Regulation, Xenobiotic Response", "Gene Expression Regulation, Developmental Signaling", "Gene Expression Regulation, Fatty Acid Signaling", "Cell Viability Process", "Aromatase Activity", "DNA Damage", "Glucocorticoid Metabolic Process", "Thyroid Receptor Modulation", "Gene Expression Regulation, Thyroid Signaling", "p53 Signaling Pathway", "Gene Expression Regulation, Other Transcription Factors", "Oxidative Stress", "Inflammatory Response", "Histone Modification", "Cell Cycle", "Thyroid-stimulating Hormone Receptor Activity", "Progesterone Metabolic Process", "Apoptosis"], "MT_NCIm_term_ID": ["CUI:C1625136", "CUI:C1158342", null, null, "CUI:C1158330", "CUI:C1154743", "CUI:C1516362", "CUI:C1149069", "CUI:C0012860", "CUI:C1158343", "CUI:C2752610", "CUI:C2984306", "CUI:C0242606", "CUI:C1155266", "CUI:C1156199", "CUI:C0007586", "CUI:C1152778", "CUI:C1158333", "CUI:C0162638"]}